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ABSTRACT
ABSTRACT
Mitochondria are organelles recognized as central players in cell death. 
Dysfunctional mitochondria are a well-known hallmark of disease since the 
accumulation of aberrant mitochondria can alter cell homeostasis thus resulting in 
tissue degeneration. Lysosomal storage disorders (LSDs) are a group of genetic diseases 
characterized by the accumulation of un-degraded material inside lysosomes that leads 
to autophagic-lysosomal function failure. In LSDs, mitochondrial aberrations have been 
associated to autophagic stress. However, the mechanisms by which autophagic 
deregulation determines mitochondrial dysfunction and how such alterations are 
involved in tissue pathogenesis remain largely unexplored. Normally, mitochondrial 
clearance occurs by a selective form of autophagy, known as mitophagy, which relies 
on a parkin- mediated mitochondrial priming and subsequent engulfment by 
autophagosomes. Here, we have performed a comprehensive analysis of mitophagy in 
a mouse model of Multiple sulfatase deficiency (MSD), an LSD characterized by both 
severe neurological and systemic involvement. We demonstrated that, in MSD liver, 
reduced parkin results in an inefficient mitochondrial turnover thus determining the 
accumulation of effete organelles outside autophagic vesicles. As consequence, 
dysfunctional mitochondria release cytochrome c into the cytosol ultimately leading to 
apoptotic cell death. Otherwise, in MSD brain, we observed minor morphological and 
functional changes that could not be directly associated to specific defects in 
mitochondrial priming machinery. Together these data provide new evidences on the 
mechanisms underlying mitochondrial dysfunction in LSDs and indicate that 
mitochondrial alterations differently contribute to tissue pathogenesis in a mouse 
model of LSD.
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Chapter 1. Lvsosomes
Lysosomes are single-membrane-delimited organelles engaged in the 
degradation of several types of macromolecules. They were first described by de 
Duve as "a special type of cytoplasmic granules with sedimentation properties 
between those of mitochondria and microsomes" (1). Lysosomes contain in their 
lumen more than 40 hydrolases including proteases, glycosidases, sulfatases, 
phosphatases and lipases. These enzymes have an optimum pH below 6 and this 
acidic microenvironment, essential for several lysosomal functions, is maintained by 
a vacuolar-type H+- ATPase enclosed in the limiting membrane. The membrane is 
formed by a single phospholipid bilayer that retains many integral proteins (i.e. 
LAMP-1 and -2) that control the passage of material into and out of lysosomes by 
both permeability and its ability to fuse with other vacuoles. This material is 
delivered from the cells own cytoplasm (i.e. autophagy) as well as macromolecules 
taken up from the extracellular space (endocytosis) by an interconnected network 
of membranes known as the endo-lysosomal system (2, 3).
1.1. Synthesis and sorting of lysosomal enzymes
Lysosomal hydrolases are glycoproteins originally synthesized with an N- 
terminal sequence of 20-25 aminoacids recognized by the signal recognition 
particle, which enables the nascent polypeptides to be translocated across the
1
___________________________________________ Chapter 1. Lysosomes
membrane o f the rough endoplasmic reticulum  (ER) (figure 1). Subsequent to  the 
removal o f the signal peptide and N-glycosylation, they move to  the Golgi 
com partm ent where they acquire a mannose 6-phosphate (M6-P) ligand. The 
acquisition o f the M6-P marker is required to  guarantee the targeting o f proteins to  
lysosomes although M6-P-independent tra ffick ing to  lysosomes has also been 
described. However, In most cases, the failure o f acquisition o f the M6-P ligand 
results in e ither m istargeting o f lysosomal enzymes or the ir secretion.
Figure 1.Model for the intracellular transport of MPR and proteins to lysosomes. Soluble 
lysosomal enzymes are synthesized and translocated into the ER lumen (1). Once in the 
Golgi (2), the MP6 tag is added (3) and recognized by MPRs. Receptor-ligand complexes are 
transported to  the early endosomal compartment (EE, 4). A lower pH produces complex 
dissociation and the lysosomal enzymes are delivered to  the lysosome (Lys; 5 and 6). MPRs 
return back to  the TGN (7 and 8) or to the plasma membrane (9). Exogenous M6P- 
containing proteins can be internalized by CI-MPR (10) and directed to  lysosomes along the 
endocytic pathway (11). Enzymes that do not bind to MPR are secreted (12).
2
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In mammalian cells two MPR exist: the 46 KDa cation-dependent MPR (CD- 
MPR, MPR46) and the 300 KDa cation-independent MPR (CI-MPR, MPR300). 
Subsequently, receptor-ligand complexes exit from the TGN in clathrin-coated 
vesicles and fuse with membranes of the endosomal compartment. Once in the 
acidic environment of lysosomes, hydrolases undergo additional post-translational 
modifications including proteolysis, folding and aggregation (2, 4, 5).
1.2. Lysosome biogenesis
Acidic hydrolases can be found in each type of cell except for erythrocytes. It 
is therefore not surprising that genes encoding some lysosomal enzymes have 
regions upstream of the coding sequence that are common to promoters of 
housekeeping genes.
■TFEB overexpression 
HTFEB silencing
2  0.4
iu-C
S^Sst-
Lysosomal genes Controls
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Figure 2.Expression analysis of lysosomal genes after TFEB over- expression and silencing.
Blue bars show the fold change of the mRNA levels of lysosomal genes in TFEB- versus 
pcDNA3- transfected cells. Red bars show the fold change of mRNA levels in mimic-miR- 
128-transfected cells versus cells transfected with a standard control miRNA (mimic-miR- 
cel-67). Randomly chosen nonlysosomal genes were used as controls. Gene expression was 
normalized relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Recently, a comprehensive analysis of promoter regions of 96 lysosomal 
genes resulted in the identification of a palindromic sequence, called CLEAR, highly 
enriched in this promoter set. Among the transcription factors that bind sequences 
similar to the CLEAR consensus, only TFEB resulted in the upregulation of lysosomal 
genes (figure 2). The increase in the number of lysosomes and the upregulation of 
some non-lysosomal enzymes tightly related to lysosomal function (i.e. M6PR) make 
TFEB a master regulator of lysosomal biogenesis (6).
4
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Chapter 2. Lysosomal storage disorders (LSDs)
Lysosomal storage disorders are a group of inherited metabolic disorders 
that result from defective lysosomal acid hydrolysis of endogenous 
macromolecules. Although the first description of a lysosomal storage disorder was 
that of Tay-Sachs disease in 1881, the link between an enzyme deficiency and a 
storage disorder was only demonstrated by Hers in 1963 (4, 5). Currently, over 40 
LSDs involving soluble hydrolases and integral membrane proteins have been 
described (Table I from ref.7).
LSDs can be classified according to the defective enzyme or protein but 
perhaps, the most useful classification is made on the basis of the kind of substrate 
that accumulates. For example, in Mucopolysaccharidoses (MPS), 
glycosaminoglycans (mucopolysaccharides) accumulate due to the impaired 
function of any 1 of 11 lysosomal enzymes that include exoglycosidases, 
sulphatases and one transferase. In some cases, a defect in a single enzyme can 
lead to the accumulation of different substrates (7).
However, it is important to highlight that these disorders are not simply a 
consequence of pure storage but result from perturbation of complex cell signaling 
mechanisms that give rise to secondary structural and biochemical changes.
5
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Table 1. Lysosomal storage disorders
Disease Defective protein Main storage materials
Sphingolipidoses
Fabry a- Galactosidase A
G lobotriasylceram ide and 
blood-group-B substances
Faber lipogranulomatosis Ceramide Ceramide
Gaucher
P- Glucosidase Glucosylceramide
Saposin-C activator Glucosylceramide
Niemann-Pick A and B Sphingomyelinase Sphingomyelin
Sphingolipid-activator
deficiency
Sphingolipid activator Glycolipids
GM1 gangliosidosis (3- Galactosidase GM1 ganglioside
GM2 gangliosidosis (Tay- 
Sachs)
(3- Hexosaminidase A
GM2 ganglioside and 
related glycolipids
GM2 gangliosidosis (3- Hexosaminidase A and GM2 ganglioside and
(Sandhoff) B related glycolipids
GM2 gangliosidosis (GM2- 
activator deficiency)
G M 2-activator protein GM2 ganglioside and 
related glycolipids
Mucopolysaccharidoses (MPS)
MPS 1 (Hurler, Scheie, 
Hurler/Scheie)
a-iduronidase
Dermatan sulphate and 
heparan sulphate
MPS II (Hunter) lduronate-2-sulphatase
Dermatan sulphate and 
heparan sulphate
MPSIIIA (Sanfilippo)
Heparan /V-sulphatase 
(sulphamidase)
Heparan sulphate
MPSIIIB (Sanfilippo)
/V-Acetyl-a-
glucosaminidase
Heparan sulphate
MPSIIIC (Sanfilippo)
Acetyl-CoA:a-glucosamide
A/-acetyltransferase
Heparan sulphate
MPSIIID (Sanfilippo)
A/-Acetylglucosamine-6-
sulphatase
Heparan sulphate
M orquio-A  disease
A/-Acetylgalactosamine-6-
sulphate-sulphatase
Keratan sulphate, 
chondroitin  6-sulphate
M orquio-B disease (3-Galactosidase 
A/-Acety Iga lactosa m i n e-4-
Keratan sulphate
MPS VI (Maroteaux-Lamy) sulphatase 
(arylsulphatase B)
Dermatan sulphate 
Heparan sulphate,
MPS VII (Sly) p- Glucuronidase
dermatan sulphate, 
chondro itin-4- and -6- 
sulphates
6
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Table 1. Lysosomal storage disorders (continue)
Disease Defective protein Main storage materials
Oligosaccharidoses and glycoproteinosis
Pompe (glycogen- 
storage-disease type II)
a- Glucosidase Glycogen
Diseases caused by defects in integral membrane proteins
Cystinosis Cystinosin Cystine
Danon disease LAMP2
Cytoplasmic debris and 
glycogen
Infantile sialic-acid-
storgae disease and Sialin Sialic acid
Salla disease
Mucolipidosis (ML) IV M ucolipin-1
Lipids and acid 
mucopolysaccharides
Niemann-Pick C (NPC) NPC1and 2
Cholesterol and 
sphingolipids
Others
Galactosialidosis Cathepsin A Sialyloligosaccharides
1 Cell and pseudo- 
Hurler polydystrophy 
(ML II and ML III,
UDP-/V-
acetylglucosamine:lysosomal 
enzyme /V-acetylglucosaminyl-
Oligosaccharides, 
mucopolysaccharides 
and lipids
respectively) 1-phosphotransferase
M ultip le  sulfatase 
deficiency
Ca-formylglicine-generating
enzyme
Sulphatides
Neuronal ceroid 
lipofuscinosis (NCL) 1 
(Batten disease)
CLN1 (protein 
palm itoylthioesterase-1)
Lipidated thioesters
NCL2 (Batten disease)
CLN2 (tripeptidyl amino 
peptidase-1)
Subunit c o f the 
m itochondria l ATP 
synthase
Subunit c o f the
NCL3 (Batten disease) Arginine transporter m itochondria l ATP 
synthase
2.1. Genetics
LSDs are monogenetic disorders usually inherited in an autosomal-recessive 
fashion except fo r Fabry disease, MPS II and Danon disease tha t are X-linked. The 
prevalence is 1 in 5000 to  8000 births in USA, Europe and Australia. D ifferent
7
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mutations have been described in the same gene and these include missense, 
nonsense and splice-site mutations, and partial deletions and insertions. 
Depending on the type of mutation, complete or partial loss of enzyme activity can 
be found. The levels of enzyme activity account for the severity of the phenotype: 
the lower the residual activity, the earlier the age of onset and the more severe the 
disease (5, 7).
2.2. Clinical features and diagnosis
In LSDs, the severity of the disease is related to the type and amount of 
substrate that accumulates and the tissues or cells in which it accumulates. The 
most severe, the infantile forms, present acute brain involvement and patients 
usually die within the first years of life. In adult forms, symptoms develop more 
slowly and disability often arises mainly from peripheral symptoms. Juvenile forms 
are intermediate between infantile and adult forms. Neurological symptoms can 
include seizures, dementia and brainstem dysfunction. Among the peripheral 
symptoms we find enlargement of the spleen and liver (hepatosplenomegaly), 
heart and kidney injury, abnormal bone formation, muscle atrophy and ocular 
disease. Several LSDs are characterized by prominent neurological involvement and 
minimal peripheral impairment (for example, Sanfilippo disease), whereas others 
have peripheral dysfunction with rare brain involvement (for example, Fabry 
disease) (7).
The identification of a LSD can be complex and lengthy. Certain symptoms, 
especially when appearing in clusters, should alert physicians to the possibility of a
8
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LSD as the underlying cause. However, many of these appear with other more 
common diseases leading to delays caused by misdiagnosis.
Table II. Presenting features in some Lysosomal storage disorders
S t e m
1f 10: hypotonia, DD, coarse facial
1 G M l gangliosidosis features, HM, CRS (±) LO: DD, ataxia, L, P, F
i dysarthria, PR, dystonia 
Late 10: weakness, hypotonia, DD, genu
....... -... - ....- ....... -.. -
Metachromatic
Leukodystrophy
recurvatum JO: weakness, PR, ataxia,
behavior changes AO: pyramidal or 
cerebellar signs, behavior changes,
L, F, U
f
psychoses, dementia 
Aggressive behavior, DD, mildly coarse
. . . —............... .........  .
| MPS IMA (Sanfilippo) facial features, F
hirsute, coarse hair, mild DM
Multiple sulfatase DD, ichthyosis, coarse facial features,
L/ Fdeficiency deafness, mild DM, PR
Mucolipidosis IV
DD, corneal opacities, retinal 
degeneration, strabismus
F
Pompe disease Hypotonia, DD, cardiac enlargement F
Abbreviations: AO, adult onset; DD, developmental delay; DM, dysostosis multiplex; F, fibroblasts; 
HM, hepatomegaly; HSM, hepatosplenomegaly; 10, infantile onset; JO, juvenile onset; LO, late 
onset; L, leukocytes; MR, mental retardation; P, plasma; PR, psychomotor regression; U, urine.
The main method of validating a clinical suspicion is enzyme assay, available 
for most LSDs. These tests compare enzyme levels in a patient sample (generally 
blood, urine, or skin fibroblasts) against normal benchmarks (Table II). Low levels of 
a particular enzyme confirm the LSD associated with that enzyme defect. In some 
cases, other methods may be used, such as brain MRIs, electroretinogram, or 
biopsy of enlarged tissue. Mutation analysis can check for a gene mutation known 
to cause a particular disorder but it is not always conclusive as several mutations 
may cause a certain LSD (8).
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2.3. Treatment
The phenotypic heterogeneity has resulted in considerable difficulty 
especially when considering treatment. Specific therapy can be broadly divided into 
those that address the symptoms and those that address the cause.
Metabolic cross-correction
• Stem cell transplantation (HSCT)
Hematopoietic cells from donors are able to build up sufficient amounts 
of enzyme to correct the deficient activity. Engraftment after 
transplantation results in a rapid decline in GAG excretion, reduction of 
liver and spleen volume, and improvement of obstructive airway 
symptoms. However, the skeleton does not respond as well and 
patients often need surgical intervention (9).
• Enzyme replacement therapy (ERT)
Exogenously enzymes are taken up by cells. The results of ERT vary 
considerably from disease to disease and depend on the age of onset, 
rapidity of progression and the presence or absence of neurological 
involvement. Recombinant enzymes are already available for some LSDs 
(Pompe, Fabry, MPSI, II and VI and Gaucher) (5, 9) (Table III).
10
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Table III. Metabolic cross-correction of some types of LSDs
1 ©fiiBais? iK p ts g fe mm m
: Mucopolysaccharidosis MPSI Yes Yes
MPS II Yes Yes
[ .... ................................ ;.. : MPS III A-D Yes -
MPS IV A-B Yes -
................ ......... ......... M PS VI Yes Yes
Glycoproteinosis Aspartylglucosaminuria Yes -
\ Fucosidosis Yes
Mannosidosis a and 3 Yes
i Sphingolipidosis Fabry's - Yes
Farber's Yes -
1............... -....... - .................
Gaucher's l-lll Yes Yes
GMi gangliosidosis Yes -
Niemann-Pick A and B Yes -
Tay-Sachs disease Yes -
n'~....■..■....... . Krabbe disease Yes -
MLD Yes -
j. Other lipidosis Ceroid lipofuscinosis Yes -
BMT, bone marrow transplantation; ERT, enzyme replacement therapy
Substrate reduction therapy (SRT)
The concept of this therapeutic principle is to reduce the amount of storage 
material instead of enhancing the activity of the degrading enzymes. For example, 
N- butyldeoxynojirimycin (Miglustat, Zavescal, Actelion Pharmaceuticals, 
Allschwil/Basel, Switzerland) has the ability to inhibit ceramide glucosyltransferase, 
the enzyme that synthesizes glucosylceramide, the storage compound in Gaucher 
disease (10). This compound has also successfully been used in other LSDs such as 
NPC as glycosphingolipids directly derivate from glucosylceramide (11).
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Chaperone-mediated therapy
Mutations that affect accurate folding prevent the lysosomal enzymes from 
reaching their final destination so that they cannot fulfill their function. 
Chaperones are small molecular weight ligands that stabilize misfolded proteins 
and ensure their correct targeting to the lysososome. One of the advantages of 
pharmacological chaperones is their better biodistribution profile in comparison 
with recombinant enzymes. Unfortunately, this therapy is likely to be effective only 
in patients with mutations outside the catalytic site (5, 9).
For example, in Fabry disease, it has been demonstrated that subinhibitory 
doses of the competitive inhibitor of ct-GalA, 1-deoxygalactonojirimycin (DGJ), 
stabilize mutant a-GalA in vitro and correct the trafficking defect (12).
Gene therapy
• In vivo Gene therapy
Vector delivery systems (i.e. retroviruses, AAVs) containing the correct 
copy of a gene are administrated to effectively transduce organs, which 
become a source of enzyme for metabolic correction. Intravenous 
delivery of AAV2 vectors has resulted in biochemical, histological, and 
clinical improvements in several murine models of LSD. Moreover, 
numerous studies have been done to test the hypothesis that directed 
brain gene transfer can be therapeutic in animal models of LSD with 
neurologic involvement. Unfortunately, in some cases, the expression of
12
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the delivered gene can be transient due to the severe immune reactions 
directed against the vector (13).
• Ex vivo Gene therapy
The goal of this strategy is to transplant autologous genetically modified 
hematopoietic stem cells that express the defective protein thus 
creating a reservoir of enzyme that can be secreted into the circulation 
and correct the disease at distant sites. Although the preclinical 
hematopoietic-directed gene therapy experiments are promising, the 
success has not translated into the clinic as pre-clinical experiments in 
small animals suggest that there is no selective advantage for enzyme- 
positive cells in LSDs (13).
However, in the last years, research in LSDs has been largely addressed to 
understand the relationship between storage and cellular dysfunction. 
Understanding what is occurring in each cell at a molecular level would allow us to 
find common features/pathways with other type of storage disorders (i.e. 
Alzheimer's, Parkinson's) and design new therapeutic strategies.
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Chapter 3. Sulfatase Deficiencies
3.1. Sulfatases family
Sulfatases are a family of enzymes that carry out the hydrolysis of sulfate 
ester bounds from a wide variety of substrates such as glycosaminoglycans, 
sulfolipids and steroid sulfates (14).
R-0S03' + H20  -> R-OH + H+ + S042'
R-NHSO3 ' + h2o ->  R-NH3+ + SO4 2'
The similarities shared by sulfatases include: 1) 20-60%  sequence homology 
over the entire protein length, 2) a highly conserved N- terminal region containing 
the consensus sulfatase motifs, and 3) a unique active-site aldehyde residue, a- 
formylglycine (FGIy), which is installed post-translationally (15). The significant 
sequence conservation strongly suggests that sulfatases are members of an 
evolutionary conserved gene family sharing a common ancestor (16).
The first sulfatases described were identified through the study of a disease 
(i.e. STS, steroid sulfatase). Years after, positional cloning strategies first and 
analysis of the human genome sequence allowed the identification of many new 
sulfatases (17). To date, 17 different sulfatases have been described in humans 
(Table IV from ref. 17)
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i Table IV. Human Sulfatases
- -- ........ ..—-................ ...... —
Gene Chromosomal
localization
Enzyme Subcellular
localization
Human disorder
ARSA 22ql3 Arylsulfatase
A
Lysosomal Metachromatic
leukodystrophy
ARSB 5q l3 Arylsulfatase B Lysosomal Maroteaux-Lamy
syndrome
IDS Xq27-28 Iduronate
sulfatase
Lysosomal Hunter syndrome
SGSH 17q25.3 Sulfamidase Lysosomal Sanfilippo A 
syndrome
G6S 12ql4 Glucosamine-
6 -sulfatase
Lysosomal Sanfilippo D 
syndrome
GAL6S 16q24 Galactose-6 -
sulfatase
Lysosomal Morquio A 
syndrome
ARSC/STS Xp22.3 Arylsulfatase C
/Steroid
sulfatase
Microsomal X-linked
Ichthyosis
ARSD Xp22.3 Arylsulfatase
D
Arylsulfatase E
ER N.I.
ARSE Xp22.3 Golgi Chondrodysplasia 
Punctata 1
ARSF Xp22.3 Arylsulfatase F ER N.I.
ARSH Xp22.3 Arylsulfatase
H
Hsulfl
N.D. N.I.
HSULF1 8ql3.2-13.3 Cell surface N.I.
HSULF2 20ql3.12 Hsulf2 Cell surface N.I.
ARSG 17q23-24 Arylsulfatase
(2
Lysosomal (?) N.I.
ARSJ 4q26
VJ
Arylsulfatase J ER N.I.
ARSI 5q32 Arylsulfatase 1 ER N.I.
TSULF 5q l5 T.Sulfatase N.D. N.I.
ER, endoplasmic reticulum; ND, not determined; Nl, not identified
Classification
• Lysosomal sulfatases
Sulfatases localized into the lysosomes are soluble enzymes that exert their 
activity (mostly catabolic) at an acidic pH. They demonstrate substrate
15
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specificity and little functional redundancy. Six diseases are due to 
deficiencies of lysosomal sulfatases. They include (17):
a) MLD (Metachromatic Leukodystrophy), in which sulfatide accumulation 
destroys myelin sheaths of the nervous system;
b) and five different types of Mucopolysaccharidoses,
i. MPS II (Hunter), heparan and dermatan sulfate storage.
ii. MPS IIIA and D (Sanfilippo), heparan sulfate accumulation.
iii. MPS IVA (Morquio), keratan sulfate storage.
iv. MPS VI (Maroteaux-Lamy), dermatan and chondroitin 
sulfate accumulation.
• Non-lysosomal sulfatases
Sulfatases localized in non-acidic subcellular compartments such as the ER, 
the Golgi and the cell surface; are membrane-bound enzymes involved in 
biosynthetic pathways (15). Extracellular matrix sulfatases (Sulfl/2) have a 
pivotal role in signaling and embryonic development based on the 
modulation of interactions between GAGs and signaling molecules. 
Mutations in the ER/Golgi sulfatases (STS/ARSC and ARSE) are, respectively, 
responsible for:
a) X-linked ichthyosis (XLI),
b) and X-linked recessive chondrodysplasia punctata 1 (CDPX1), 
characterized by abnormalities in cartilage and bone development (17).
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Animal models
Currently, animal models for sulfatases deficiencies are available except for 
the two non-lysosomal sulfatases deficiencies. Although rare genetic disorders are 
as infrequent in animals as they are in humans, most of these animal models are 
spontaneous models (table V from ref.17). Fortunately, these animal models 
resemble the human phenotype thus becoming of great importance for the study of 
new therapeutic approaches for these types of disorders.
i Table V. Animal models of sulfatases deficiencies
Sulfatase disorder Animal model
MLD Mouse
MPS VI Cat*, rat*, dog*, mouse
MPS II Dog*, mouse
MPS III A Dog*, mouse*
MPS III D Goat*
MPS IV A Mouse
XLI Not available
CDPX Not available
* spontaneous models
3.2. Sulfatase Modifying Factors (SUMFs)
Two highly homologous amino acid motifs, recognized as the sulfatase 
signature sequences I and II, are found within the first third of the N-terminal 
sequence of all known hydrolytic sulfatases (18). The signature sequence I (C/S-X-P- 
S/X-R-X-X-X-L/X-T/X-G/X-R/X) is critical for directing the post-translational
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modification of the initial cysteine or serine residue into the catalytically active 
residue formylglycine (FGIy) (19, 20). This step occurs within the ER before the 
sorting to different cellular compartments and is directed by the product of the 
SUMF1 gene.
The identification of the SUMF1 gene was carried out by two different 
approaches, one biochemical (21) and the other genetic (22). In this case, Cosma 
and collaborators used a panel of human/mouse hybrid cell lines containing 
individual normal human chromosomes tagged with the dominant selectable 
marker HyTK and fused to an immortalized cell line from a patient with Multiple 
Sulfatase Deficiency (MSD) (see chapter section 3.3).
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Figure 3. Mapping of the MSD gene by microcell-mediated chromosome transfer.
ARSA, ARSB and ARSC activities are expressed in enzymatic units x mg total protein'1 x 3 
hr'1. Chromosome 3 clones complement the MSD defect (from ref. 22).
All 22 human autosomes were transferred one by one to the patient cell line 
and hybrids were selected in hygromcyin and HAT-containing medium. 
Subsequently, cells were harvested for ARSA, ARSB and ARSC enzymatic assay.
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Several clones deriving from the chromosome 3 transfer were significantly higher 
compared to clones from all other chromosomes (figure 3).
Further analysis determined 3p26 as the specific chromosomal region 
containing the SUMF1 gene. This gene is composed of 9 exons, spans approximately 
106 kb and encodes a glycoprotein of 374 aminoacids, the formylglycine-generating 
enzyme (FGE). Northern blot analysis revealed an ubiquitous expression pattern of 
SUMF1 with a higher abundance in kidney and liver (22).
Highly conserved SUMF1 homologues were found in many eukaryotic and 
prokaryotic species, which is not surprising given the importance of the FGIy 
modification. Catalytic and functional conservation among FGE homologues was 
demonstrated by the production of active human sulfatases co-expressed with 
SUMF1 cDNAs from mice and Drosophila (figure 4) (22).
A R S A  g l R g f c
human sulfatase activities in 
Cos-7 cells (from ref.22).
Figure 4. Murine SUMF1, 
Drosophila SUMF1 and 
human SUMF2 enhance
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Sequence comparison identified the presence of a SUMF1 gene paralogue 
located on human chromosome 7 q l l  that was designated SUMF2. The product of 
this gene also showed FGE activity, albeit much less efficient than that of SUMF1 
(22).
3.3. The Multiple Sulfatase Deficiency (MSD)
Genetics
The Multiple Sulfatase Deficiency (OMIM #272220) is an autosomal 
recessive disorder caused by mutations in the SUMF1 gene (figure 5).
exon 1 2 3 4 5  6 7 8
-
M
M1R 276delC 
M1V
iii i ii mu utr
C218Y A279V C336R R345C
661delG R327X A348P
S155P c.603-2delA R349Q
c.519+4delGTAA R349W
S359X
Figure 5. Localization of the mutations associated with MSD.
Most MSD patients have residual sulfatases activity due to hypomorphic 
mutations in the SUMF1 gene thus suggesting that complete loss of SUMF1 function 
is likely to be lethal in humans (23). Nevertheless, this residual activity is not 
sufficient for the proper modification of sulfatases.
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Clinical features
Patients suffering from  MSD combine clinical symptoms o f the  d iffe rent 
single sulfatase defects and can be classified into fou r clinical form s (table VI from  
ref.24): very severe neonatal MSD, whose diagnosis is established in the firs t 
months o f life and whose sym ptom atology is very sim ilar to  mucopolysaccharidosis 
(MPS) w ith  death w ith in  the  firs t 12 months o f life; severe la te-in fantile  MSD, 
whose onset is in the firs t year o f life and neurological problems are sim ilar to  the 
late-infantile  form  o f m etachrom atic leukodystrophy (MLD); mild la te-infantile  
MSD, w ith  symptoms occurring between the age o f 2 and 4 years, absence o f 
in trauterine manifestations, facial dysmorphism, visceromegaly, and cardiopathy, 
and presence o f a m ilder/s low er neurodegeneration; and juvenile MSD, which is a 
rare subtype associated w ith  a few  o f the symptoms o f MSD, such as ichthyosis and 
mental retardation (25).
Table VI. Classification o f MSD patients and associated clinical phenotype
Symptoms Neonatal Late Infantile Late Infantile Juvenile
(very severe) (Severe) (M ild ) (M ild )
Retardation +++ +++ +++ ++
Neurodegeneration +++ +++ +++ ++
Ichthyosis +++ +++ ++ +
Dysmorphism +++ +++ - +
Organomegaly +++ +++ - -
Skeletal changes +++ ++ + -
Intrauterine
manifestation
+++ +++ - -
Heart disease +++ - - -
Corneal clouding +++ - - -
Hydrocefalus +++ - - -
Age at onset: +++ <2 years, ++ 2-4 years, + >4 years, - not observed).
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No genotype-phenotype correlation has been established so far with any 
clinical form, but the severe neonatal subtype appears to be related to nonsense 
mutations and large deletions as well as to missense mutations that directly affect 
the active site of FGE (26).
Diagnosis
Biochemically, MSD is distinct and classifiable. Patients with MSD show a 
mixed excretion of glycosaminoglycans (GAGs) and storage of the different 
sulfatase substrates. The residual activities of different sulfatases measured in 
leukocytes and fibroblasts of patients can be sub-grouped into two classes with less 
than 15% compared to normal activities into group I (severe) and more than 15%, 
sometimes reaching normal values, into group II (mild) (reviewed in 24).
Treatment
Currently, there are no available therapies for the treatment of MSD. 
However, a patient treated with human recombinant arylsulfatase B (Galsufase) 
showed significant improvement (26). In that case, the main clinical manifestations 
were similar to those of MPS VI but, in general, the severity of the phenotype 
makes MSD unsuitable to be treated by enzyme replacement or bone marrow  
transplantation.
Recently, an in vivo gene-therapy approach has been tested on an MSD 
mouse model. Combined administration (intra-cerebral and systemic) of an AAV9
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vector encoding SUMF1 resulted in the global activation of sulfatases and the near- 
complete clearance of GAGs (27).
3.4. The Sumfl-/- mouse: an animal model for Multiple Sulfatase 
Deficiency (MSD)
In 2007, in our lab, a transgenic mouse (C57B6/S129j background) carrying a 
null mutation in the SUMF1 gene was generated.
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Figure 6. Growth and survival rates in Sumfl-/- mice, (a) Kaplan-Meyer survival curve of 
Sumfl-/-m\ce. (b) Mean weight values of WT (purple) and individual weight values of 
Sumfl-/- mice (blue), (c) Sumfl-/- mice (KO) are smaller than their WT littermates at P40. 
(d) Sumfl-/- mice (on the left) display the typical flat facial profile of patients affected by 
MPSs.
Although Sum fl-/- mice differ from patients for the total absence of SUMF1 
protein (FGE), they share a common phenotype: Sum fl-/- mice display congenital
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growth retardation and frequent mortality in the first weeks of life, with only 1 0 % 
reaching 3 months of age (figure 6 ) (28). Hind limb clasping, head tremor and 
seizures were also detected, indicating neurological involvement. 
Hepatosplenomegaly and skeletal abnormalities are other typical features of this 
disorder due to the accumulation of storage material in peripheral organs. Strong 
signs of inflammation have been observed in all tissues of S um fl-/- mice. Detailed 
analysis of the accumulated material pointed out macrophages as the primary site 
of GAG storage, thus indicating a link between storage and inflammation. 
Moreover, immunohistochemical analysis revealed a remarkably astroglyosis, 
progressive loss of Purkinje cells and massive apoptosis at a late stage of disease 
(28).
As SUMF1 regulates not only lysosomal sulfatases but also sulfatases 
localized in other cellular compartments (i.e. extracellular matrix, ER/Golgi), some 
of the clinical features observed in MSD may be due to alterations in signaling 
pathways since GAGs are involved in developmental processes.
II
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&  & &  WL* Figure 7. Skeletal development in
m  m Sumfl-/- mice. (G) Newborn, (H) and
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!
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A study of Settembre and collaborators in 2008 (29) have shown that some 
of the skeletal abnormalities observed in Sum fl-/- mice are due to altered 
proteoglycan desulfation, a critical step for chondrocyte differentiation and 
proliferation (figure 7).
Research on MSD has underlined the general importance of studying 
inherited diseases even if only very few patients are affected. However, many 
questions need to be answered to unravel the steps from the basic molecular 
defect to the manifestation of the disease in order to gain deeper insight into 
complex pathophysiological mechanisms. Hence, the MSD mouse [Sum fl-/-) 
represents a good animal model to study the pathogenic mechanisms of this rare 
genetic disorder as it recapitulates most of the clinical features described in MSD 
patients.
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Chapter 4. Autophagy and Mitochondria in LSDs
In order to maintain cell homeostasis, a well-controlled balance between 
protein synthesis/degradation and organelle biogenesis/turnover is required. The 
cell's major pathways of degradation are autophagy-lysosome system (ALS) and the 
proteasome. Whereas proteasome degradation depends on specific tagging of 
target proteins by ubiquitin molecules, autophagy is a dynamic process by which 
parts of the cytoplasm and organelles are delivered to lysosomes for their 
degradation (30) (figure 8 ).
Prcautophagosomc Cytosolic chaperone
Cytosolic protein
Autophagy complex
Ubiquitin
tS L .
Maoroautophagy Autophagic
vacuole Proteasome
LAMP»2A
Microautophagy Bndocytosjs
Lysosome
O 1 Plasma membrane
Heterophagy
Figure 8. Proteolytic systems in mammalian cells (31)
Depending on the delivery route, three different autophagic routes are known 
(reviewed in 32):
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1 ) macroautophagy (usually referred simply as autophagy), in which a double­
membrane vesicle, called autophagosome, encircles part of the cytoplasm and 
fuses with lysosomes for the degradation of its content;
2 ) microautophagy, in which the lysosomal membrane itself sequesters a 
portion of the cytoplasm;
3) chaperone-mediated autophagy, by which only proteins with a specific 
sequence signal are recognized by cytosolic chaperones and transported from  
the cytosol to the lysosomal lumen.
The process of macroautophagy can be divided into at least 4 steps: 
induction, formation of the autophagosome, autophagosome docking and fusion 
and autophagic body breakdown (30) (figure 9).
Starv;
signal
racuolePlasma membrane
Autophagic bodyAutophagosome
1. Induction 2. Formation 3. Docking and fusion 4. Breakdown
and recycling
Figure 9. Schematic model of macroautophagy.
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1) Induction o f macroautophagy
This process is both deve lopm enta l^ and nutritiona lly  regulated. Under 
nutrient-rich conditions, autophagy is inhibited by mTOR (mammalian 
target o f Rapamycin), a member o f the phosphatidylinosito l 3-kinase- 
related kinase protein w ith  a conserved role in sensing cellular 
nutrients, energy levels and redox status. During starvation instead, 
mTOR kinase is inactivated and autophagy is induced. Downstream of 
TOR kinase, more than 20 ATG genes (yeast) encode proteins essential 
fo r the execution o f autophagy (figure 10).
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Figure 10. ATG proteins take part in the induction and form ation of new 
autophagosome membranes.
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In the initial steps of autophagy we find numerous proteins including:
• A tg l-A tgl3-A tgl7, a serine/threonine kinase complex 
(ULK1 complex) that responds to upstream signals (i.e. 
mTOR)
• Atg6-Atgl4-Vps34-Vpsl5, a lipid kinase- signaling 
complex (PI3K complex) that mediates vesicle 
nucleation. Beclin-1 is the mammalian orthologue of 
the yeast Atg6 gene and when over-expressed, it can 
induce autophagy. Moreover, Beclin-1 can bind to Bcl- 
2 , an important regulator of apoptosis, leading to the 
inhibition of autophagosome formation (reviewed in 
32).
2) Formation of the autophagosome
After induction, a double-membrane vesicle begins to form in the 
cytosol. The origins of this membrane is still unknown but for 
mammalian cells it is generally thought to be the ER (33) and/or 
mitochondria (34), despite a recent study has demonstrated the 
involvement of plasma membrane (35). LC3, a mammalian homologue 
of yeast Agp8 p, is widely used as a marker for tracking autophagosomes 
(36). There are two forms of LC3: the cytosolic LC3-I and the membrane 
bound LC3-II. During autophagy, LC3-I gets lipidated and converted to
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LC3-II, which is found specifically on autophagosomes. Therefore, the 
amount of LC3-II is correlated with the extent of autophagosome 
formation.
3) Autophagosome docking and fusion
Once autophagosomes have sequestered their cargo, this is delivered to 
lysosomes. Specific proteins on both autophagosome and lysosome 
membranes are required for the proper docking and/or fusion. These 
proteins are called SNARE (Soluble NSF Attachment Protein REceptors) 
and are a large superfamily of more than 60 members that mediate 
vesicle fusion. Besides SNARE proteins, fusion also depends on 
microtubule and maintenance of proper acidification of vesicles 
(reviewed in 30).
4) Autophagic body breakdown
Fusion with lysosomes causes the release of the single-membrane 
bound inner vesicle of the autophagosome (called autophagic body) into 
the vacuole lumen while the outer membrane is incorporated into the 
limiting membrane of the receptor vesicle. Once inside the lumen, cargo 
is broken down by the activity of acidic hydrolases.
Autophagy has many physiological functions in mammalian cells (resumed in 
figure 11 from 32). Among the main functions of this pathway we highlight its 
pivotal role in:
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• Stress response. Production of energy and nutrients during stress 
conditions (i.e. starvation).
• Quality control. Turnover of organelles and aggregate-prone proteins.
• Innate and adaptive immunity. Delivery of cytosolic proteins for MHC 
class II presentation.
• Cell death. Clearance of apoptotic cells during embryonic development in 
mice and cross- talk between Atg proteins and apoptotic factors.
• Aging and longevity. Increased autophagic turnover of cytoplasmic 
constituents contributes to longer life.
Autophagy
Longevity
Organelle turnoverAntigen
presentation
Regulation of 
cell size
Programmed 
cell death
Survival during
short-term
starvation
Defence against
intracellular
pathogens
Clearance of
aggregate-prone
proteins
Protection against 
metabolic stress 
and DNA damage
Figure 11. A summary of the functions of autophagy.
Maintenance of proper activity of this pathway is essential to guarantee cell 
survival. When autophagy is impaired (i.e. mutations in ATG genes or 
reduction/increasement of the autophagic flux), cell homeostasis is altered and this 
imbalance can lead to a pathogenic state and subsequently to cell death.
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4.1. Mitophagy as a selective form of autophagy
Among the principal functions of mitochondria we find: 1) energy 
production by oxidative phosphorilation, 2) calcium signaling, 3) regulation of 
cellular metabolism and proliferation, and 4) apoptosis-programmed cell death. 
Mitochondrial life cycle consists of a series of fusion and fission events that allows 
the maintenance of a healthy population of mitochondria (figure 12). Mediators of 
fusion and fission were first described in D. melanogaster (37). In mammals, 
mitochondrial fusion involves multiple steps, including mitochondrial tethering and 
fusion of OMMs, docking and fusion of IMMs and mixing of intramitochondrial 
components. The fusion machinery is composed by mitofusins MFN1/2, located on 
the OM M  (38), which form trans complexes on adjacent mitochondria during fusion 
processes; and OPA-1, which controls IMMs fusion (39). On the other side, fission 
processes are driven by the OMM protein Fisl and the cytosolic protein DLP1, 
which is recruited to mitochondrial surfaces and associates with Fis 1 (40, 41).
Twig et al (42) have demonstrated that fusion triggers fission and that 
fission is essential for autophagy. Fission events can produce metabolically different 
daughter units; one with high membrane potential (Aijjm) and the other with low 
Aijjm. Whereas mitochondria with high Ai|jm can re-enter the cycle by fusing with 
the mitochondrial network, the one with low Aijjm is less likely to re-fuse and is 
targeted by autophagy. This means that fusion is a selective process that depends 
on the metabolic state of the organelle and that fission targets depolarized 
mitochondria for digestion and elimination.
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MITOCHONDRIAL LIFE CYCLE
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Figure 12. Scheme of the different steps of mitochondria life cycle.
How are depolarized m itochondria recognized by the autophagic 
machinery? Although long assumed to  be a random process, increasing evidence 
indicates tha t m itochondria l autophagy (also called m itophagy) is a selective 
process. This idea gave raise as a result o f a study carried out by Kissova et al (43), 
who identified an outer membrane protein, U th lp , as an essential prote in fo r 
e ffic ient m itophagy in yeast. Recently, tw o  independent studies have described the 
existence o f a specific receptor fo r autophagy on the m itochondria l surface o f yeast 
(44, 45). However, a mammalian homologue fo r this receptor, known as Atg32, has 
not been found yet. Interestingly, it seems tha t selective recognition o f damaged 
mammalian m itochondria depends on the PINKl-dependent recru itm ent o f Parkin. 
Many studies have addressed this issue in the last tw o  years (46-49). PINK1 (PTEN- 
induced putative kinase 1) is a putative serine/threonine kinase w ith  a
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mitochondrial targeting sequence that recognizes depolarized mitochondria and 
promotes the translocation of cytosolic parkin onto the mitochondrial surface. The 
fact that PINK1 and parkin act in a common genetic pathway was demonstrated in 
Drosophila PINK1 mutants, which shared marked similarities with parkin mutants. 
Moreover, parkin could compensate for the PINK1 loss-of-function phenotype but 
not viceversa (50).
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Figure 13. PINKl-dependent Parkin recruitment of mitochondria for autophagic 
degradation (from ref.51)
Among the principal substrates of parkin, an E3 ubiquitin ligase, VDAC1 and 
mitofusins have been pointed out as the main candidates. Poly-ubiquitin-positive 
clusters of mitochondria are then recognized by the autophagic adaptor 
p62/SQSTMl and directly targeted to autophagosomes for degradation (figure 13).
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Mutations in the parkin gene (PARK2) and PINK1 (PARK6) are associated with 
autosomal recessive inheritance of Parkinson's disease (PD). Parkin loss-of-function 
Drosophila exhibit increased sensitivity to ROS, dopaminergic cell loss and swollen 
mitochondria with fragmented cristae (52). Thus, dysfunctional parkin, or its non­
recruitment, prevents proper targeting of irreparably damaged mitochondria for 
mitophagy, leading to a buildup of toxic, dysfunctional mitochondria, ultimately 
leading to death. Alterations in mitochondrial function have also been described in 
Alzheimer's disease and Huntington's disease (53) suggesting the involvement of 
mitochondria dynamics in the pathogenesis of these neurodegenerative disorders.
4.2. Autophagy impairment in Lysosomal Storage Disorders
Autophagy has become a growing research field in the past years. This 
process has been studied in many diseases such as neurodegenerative disorders, 
inflammatory diseases and cancer (reviewed in 54). However, the reason behind 
autophagic failure can be very diverse because of the different steps required for 
autophagy and the molecular players involved in each of them. Understanding the 
step(s) affected in each disorder could explain differences in the course of these 
pathologies and will be essential to develop targeted therapeutic approaches for 
each disease based on modulation of autophagy. Among the possible defects that 
could be behind macroautophagy we can find: 1 ) reduced autophagy induction; 2 ) 
enhanced autophagy repression; 3) altered cargo recognition; 4) inefficient 
autophagosome/lysosome fusion, and 5) inefficient degradation of the autophagic 
cargo (figure 14 from re f.55 ).
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Figure 14. Possible alterations in macroautophagy under pathological conditions.
As lysosomes are the final destination fo r autophagic cargo, autophagy has 
become an attractive target fo r new studies in LSDs. This pathway had already been 
studied in some neurodegenerative disorders such as Alzheimer's, Parkinson's and 
Huntington's (55). A lthough the etiology o f LSD is d ifferent, the sim ilarities shared 
w ith  these disorders have given rise to  a new line o f research. To date, autophagy 
has been studied in Mucopolysaccharidosis type IIIA (MPS IIIA) (56), G M r  
Gangliosidosis (57), Niemann-Pick Disease type C (NPC) (58), Neuronal Ceroid 
Lipofuscinosis (NCL) (59), Mucolipidosis type IV (60), Danon Disease (61) and 
M ultip le  Sulfatase Deficiency (56). In all disorders, an increase in the num ber o f 
autophagosomes has been described (reviewed in 62). However, whereas in some 
cases the accumulation o f autophagic vesicles was due to  a block in autophagosome 
m aturation (i.e. NCL), in o ther cases it was a consequence o f autophagy induction
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(i.e. NPC). Nevertheless, despite numerous studies in LSDs animal models, the 
precise mechanism leading to malfunction of the autophagic pathway remains still 
elusive.
Autophagy impairment in Multiple Sulfatase deficiency
In a study carried out in 2008 and published on Human Molecular Genetics we 
speculated an impairment of the autophagic pathway in two different mouse 
models of LSDs: Multiple Sulfatase Deficiency (MSD) and Mucopolysaccharidosis 
type IIIA (MPS IMA) (56). Using different approaches we showed the accumulation of 
autophagosomes in MSD tissue (brain) and cells (embryonic fibroblast and liver 
macrophages). We postulated that this abnormal accumulation of vesicles was due 
to defective clearance caused by impaired autophagosome-lysosome fusion. The 
results obtained supported our hypothesis:
1) Reduced co-localization of LAMP1 (lysosomal marker) and LC3-II 
(autophagic marker) in MSD MEFs.
2) MSD MEFs had increased levels of autophagy substrates like mutant 
proteins (a- synuclein and huntingtin) overexpressed.
3) Chemical induction of autophagy by rapamycin increased LC3-II 
levels in both control and MSD MEFs.
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Treatment of MSD MEFs with Bafilomycin A1 (an inhibitor of 
autophagosome-lysosome fusion), alone or in combination with 
rapamycin; equally increased the number of autophagosomes (63).
Accumulation of endogenous autophagic substrates (poly- 
ubiquitinated proteins, p62/SQSTMl aggregates and mitochondria) 
in MSD brain (figure 15).
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Figure 15. Mitochondrial membrane potential in MSD MEFs. Control and 
MSD MEFs were grown in either normal serum or starved conditions (4 h). 
Cells were then stained with 40 nM DiOC6 and 1 mg/ml propidium iodine. 
Aipm was measured by flow cytometry. Propidium iodine was used as 
counterstain. All experiments were performed in triplicate and analyzed 
using Stat-View software and ANOVA test. Results were considered 
significant if P < 0.05.
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According to these results, lysosomal accumulation of undegraded material 
results in defective fusion between autophagosomes and lysosomes and causes a 
block of the autophagic pathway. Our data suggest that LSDs may share common 
mechanisms with other neurodegenerative disorders (i.e. Alzheimer's, Parkinson's 
and Huntington's) raising the possibility of overlapping therapeutic strategies.
A study recently published by our group (64) further confirms the block of 
autophagy in LSDs and demonstrates that this impairment is caused by dysfunction 
of SNARE proteins involved in the autophagosome/lysosome fusion machinery.
4.3. Mitochondrial aberrations in LSDs
Mitochondrial aberrations have already been described in some LSDs. In 
GMl-gangliosidosis, measurement of cytochrome c oxidase activity in brains from  
6-gal-/- mice revealed decreasing mitochondria functionality, which was parallel to 
disease progression. Primary astrocytes obtained from these mice showed 
abnormally small fragmented mitochondria with reduced membrane potential (57). 
Cultured skin fibroblasts from MLIV patients have been used to investigate the 
mitochondrial-autophagosomal axis in mucolipidoses. In these cells, mitochondria 
appeared fragmented and had reduced buffering capacity (60). Similar results were 
obtained in MLII, MLIII and NCL2 fibroblasts (65).
All these studies suggest that the presence of dysfunctional mitochondria 
may be due to defects in the autophagic pathway as the modulation of this pathway 
can rescue the mitochondrial phenotype.
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However, most of these data describe the accumulation of mitochondria as 
a merely consequence of autophagy impairment. A detailed study on mitochondrial 
autophagy in LSDs would allow us to see whether mitochondrial 
priming/engulfment is altered in these types of disorders. Currently, it is unclear 
whether mitochondria are eventually degraded or if mitophagy fails to efficiently 
eliminate mitochondria.
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AIM OF THE THESIS
A IM  OF THE THESIS
1) To elucidate whether the accumulation of dysfunctional mitochondria is a 
consequence of impaired mitochondrial targeting to autophagosomes and, 
in turn, whether this impairment is due to defects in the mitophagic 
machinery.
2) To establish the role of dysfunctional mitochondria in MSD pathology.
41
Materials & Methods
MATERIALS &  METHODS
1. Sumfl-/- mice genotyping
1.1. Genomic DNA extraction
Tails were cut off from mice around P20 and lysed in 500pl lysis buffer (50mM  
TrisHCI pH 8, lOOmM EDTA, lOOmM NaCI, SDS 1%,) supplemented with 20 pi 
proteinase K (20mg/ml) at 55°C O/N. After removal of cellular debris (5 minutes 
centrifugation at maximum speed), DNA was precipitated by adding 1 ml of 100% 
ethanol (EtOH) to each tube and gently mixed by inverting the tubes. Subsequently, 
DNA was washed once with 70% EtOH, air-dried and resuspended in 500 pi H20.
1.2. PCR Amplification
We genotyped the mice by PCR on tail DNAs using 3-gal-specific primers 
coupled with Sum fl- specific primers (figure 16):
Int3rev S'- AGA AAC CAC CTC ACC AAA GCA GAG- 3'
lnt3for S'- TTT GTG CCT TTA CTG CCC TCT TGG-37,
Bgeorev 57-CAA AGT CAG GGT CAC AAG GTT CAT-37.
PCR conditions using the Takara LA Taq mixture (Takara Bio Inc., Japan):
1) 95 °C 2 min;
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2) 95 °C 30 sec/68 °C 30 sec/68 °C 1 min for 30 cycles;
3) 72 °C 10 min.
Resolution in a 1.5% agarose gel: 1153 bp band (Sum fl+/+ ), 800 bp band 
{Sumfl-/-) or both [Sumfl+/-).
Sumfl wt 
allele
6~geo {SHU—//-
c d T  g li
Sumfl trapped 
allele
PCR primer
F I GENOTYPES (primer d + e + f)
►WT ALLELE 
TRAPPED ALLELE
Figure 16. Gene trapping insertion site within the SUMF1 gene. Genomic PCR analysis of 
DNAs from Sumfl+/+, Sumfl+/- and Sumfl-/- littermates demonstrates that the insertion 
site is in intron 3 of the Sumfl gene
2. Generation of immortalized MEFs (Mouse Embryonic 
Fibroblasts)
MEFs were isolated by trypsinization of littermate embryos collected at E14.5 
and grown in DMEM supplemented with 20% FBS and 1% penicillin/streptomycin. 
Immortalization was performed by transfection of the pMSSVLT plasmid containing
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the SV40 gene. Selection of immortalized clones by neomycin treatment was carried 
out for 3 weeks and the immortalized cells were maintained in DMEM  
supplemented with 10% FBS and antibiotics.
3. Immunoblotting of total lysates
3.1.Total protein extraction of tissue samples
Mice were anesthetized with avertin (20pl/g weight) and then perfused with 
PBS. Brain and liver samples were collected and homogenized in ice-cold lysis buffer 
(50mM TrisHCI pH 7.4, 150mM NaCI, Im M  EDTA, 1% Triton X-100, 0.1% SDS, 0.5% 
Na deoxycholate) in presence of protease inhibitors (Sigma-Aldrich, MO, USA). 
Mechanical disruption of samples was perfomed using the TissueLyser equipment 
(Qiagen, Netherlands). Homogenates were incubated on ice for 30 minutes and 
then centrifugated at maximum speed to eliminate cellular debris. Proteins were 
quantified by the Bradford method (Bio-Rad, CA, USA) and stored at -80°C.
3.2. SDS-PAGE electrophoresis
Mini-protean SDS-PAGE gels were prepared according to protocol. Proteins 
(10-50pg) were prepared in sample buffer 4x containing P-mercaptoethanol, boiled 
for 5 minutes and loaded. Pre-stained protein marker (175-7KDa) was from New  
England Biosciencies (MA, USA). Electrophoresis was run at 80V for almost 3 hours 
at RT. Proteins on SDS-PAGE gels were transferred to PVDF membranes (Millipore, 
MA, USA) at 30V O/N 4°C. The day after, membranes were blocked in TBS/Tween
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5% milk for 1 hour at RT followed by incubation with primary antibody (1-2 hours). 
Filters were washed 3 times in TBS/Tween and incubated with secondary HRP- 
conjugated antibody (GE healthcare, Wl, USA). Detection was performed using the 
enhanced chemioluminescence (ECL) from Pierce (Thermo Scientific, MA, USA).
Primary antibodies used on tissue total lysates were: rabbit anti-COXIV 
1:1,000 (#4844 Cell Signaling Technology Inc., MA, USA), rabbit anti-LC3 1:1,000 
(NB100-2331, Novus biologicals, CO, USA), mouse anti-Parkin 1:1,000 (#4211, Cell 
Signaling Technology, MA, USA), rabbit anti-BECNl 1:1,000 (sc-11427, Santa Cruz 
biotech., CA, USA), mouse anti-OPA-1 1:1,000 (612607, BD Biosciences, NJ, USA), 
mouse anti-DLPl 1:1,000 (611112, BD Biosciences, NJ, USA) and mouse anti-|3-actin 
1:10,000( A1978, Sigma-Aldrich, MO, USA).
4. Immunoblotting of subcellular fractions
4.1. Subcellular fractioning
Brain and liver samples were collected from PBS-perfused mice. Tissue was 
weighted and homogenized in 10 volumes of ice-cold hypotonic buffer (300mM  
sucrose, lOmM HEPES pH 7.4, 0.2mM EDTA) in presence of protease inhibitors 
(Sigma-Aldrich, MO, USA). Samples were mechanically disrupted with micropestles 
(Eppendorf, Germany) and then passed through a 20G- and a 26G-needle for 
several times. The same amount of protein (1 mg) was processed in an equal 
volume of buffer for all samples. The supernatant of the first centrifugation (5 
minutes, 600 g) was further centrifugated at 16,000 g for 15 minutes. Supernatants
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were conserved as the cytosolic fraction. Pellets were washed in buffer and re­
centrifugated. The resultant pellets (mitochondria) were resuspended in the same 
volume of lysis buffer (50mM TrisHCI pH 7 .4 ,150mM NaCI, Im M  EDTA, 1% Triton X- 
100, 0.1% SDS, 0.5% Na deoxycholate). Samples were quantified by the Bradford 
method (BioRad, CA, USA) and stored at -80°C.
4.2. SDS-PAGE electrophoresis
Sample preparation and electrophoresis run were performed as described in
3.2. For parkin immunoblotting, same amounts of protein were loaded (10-20pg). 
For cytochrome c and ubiquitin immunoblotting, same volumes of each subcellular 
fraction were loaded (10-20pl).
The antibodies used were: mouse anti- Cytochrom c 1:1,000 (Cat.556433 BD 
Pharmingen, NJ, USA), mouse anti-Parkin 1:1,000 (#4211, Cell Signaling Technology, 
MA, USA) and rabbit anti-Ubiquitin 1:500 (Z0458, Dako cytomation, CO, USA). 
Rabbit anti- COX IV 1:1,000 (#4844 Cell Signaling Technology Inc., MA, USA) and 
mouse anti- ATPase p subunit 1:10,000 (abl4730, Abeam, UK) were used as 
mitochondrial markers.
5. Electron Microscopy
5.1. Tissue processing
Tissue was fixed in 1% gluteraldehyde solution (in 0.2 M HEPES) and postfixed 
in Os04 and uranyl acetate. After dehydration in graded series of ethanol, tissue
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samples were cleared in propylene oxide, embedded in Epoxy resin (Epon 812) and 
polymerized at 60°C for 24 h. From each sample, ultrathin sections (70 nm- thick) 
were cut with a Leica EM UC6 ultramicrotome. EM images were acquired using a FEI 
Tecnai-12 electron microscope equipped with an ULTRA VIEW CCD digital camera 
(FEI, Einhoven, The Netherlands). All these steps were performed by both Dr. Elena 
Polishchuk and Dr. Roman Polishchuk.
5.2. Analysis of mitochondrial morphology
Quantification of the mitochondrial dimensions (diameter) was performed 
using the AnalySIS software (Soft Imaging Systems GmbH, Munster, Germany). The 
morphological analysis was performed by Dr. Elena Polishchuk.
5.3. Analysis of autophagosome content
EM images were qualitatively analyzed and autophagosomes were classified 
as "empty" (electron-clear vesicles) or "filled" (electron-dense vesicles).
6. Real-time PCR
6.1. RNA extraction and retrotranscription (RT-PCR)
Total RNA was extracted from tissue using the RNeasy® kit (QIAgen, 
Netherlands): homogenization of samples was performed mechanically using the 
TissueLyser equipment and processed according to manufacturer's manual. RNA
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samples were quantified using a NanoDrop 8000 spectophotometer (Thermo
Scientific, MA, USA) and 1 pg of each sample was retrotranscribed with the
QuantiTect® Reverse Transcription kit (Qiagen, Netherlands).
6.2. cDNA amplification
Amplification of cDNA was performed using the SYBR Green I Master for 
LightCycler® 480 (Roche, Switzerland). Primer sequences were designed using the 
GenScript Primer Design tool (https://www.genscript.com/ssl-bin/app/primer):
PARK2
o forward 5'- GCA GCC ATA CCC TGC CGG TG-3'
o reverse 5'- TGT GGC AGG GGC CTT TGC AG-3'
PGCla
o forward S'- CCC AGA GTC ACC AAA TGA CCC CA-3'
o reverse 5'- TGA GGA GGA GTT GTG GGA GGA GT-3'
7. Analysis of mitochondrial functionality
7.1. Mitochondria isolation
Isolation of tissue mitochondria was performed using the Mitochondria 
Isolation kit protocol (MITOISOl, Sigma-Aldrich, MO, USA). Briefly, small amounts of 
tissue samples (75-150mg) were homogenized in Extraction Buffer A using
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micropestles (Eppendorf, Germany) and 20G- and 26G- needles. After a series of 
centrifuges, the final pellet of mitochondria was resuspended in storage buffer 
(lOmM HEPES pH 7.4, 250mM sucrose, Im M  ATP, 0.08 mM ADP, 5mM sodium 
succinate, 2mM K2HP04, Im M  DTT) and proteins were quantified by the Bradford 
method (Bio-Rad, CA, USA). All functional assays were performed by 4 hours after 
mitochondria isolation.
7.2. Analysis of mitochondrial membrane integrity
Mitochondria (lOpg) obtained from MSD and control mice (n=3) were 
incubated with the JC-1 working solution (Sigma-Aldrich, MO, USA) for 7 minutes. 
Subsequently, fluorescence (excitation: 485, emission: 590) was measured in a 
Fluoroskan Ascent FL fluorometer (Thermo Scientific, MA, USA).
7.3. Analysis of mitochondrial ATP content
Mitochondria obtained from MSD and control mice (n=3) were resuspended 
in an ATP-free storage buffer. ATP was measured using the ATP determination kit 
(Invitrogen, CA, USA). The assay is based on luciferase's requirement for ATP in 
producing light from the reaction:
Luciferin + ATP + 0 2 -> oxyluciferin + AMP + pyrophosphatase + C02 + light
Luciferase was added to mitochondria samples (5-10pl) and luminescence was 
measured in a GloMax 96-well luminometer (Promega, Wl, USA). Results were 
normalized by the amount of mitochondrial protein.
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8. Detection of apoptotic cells
Paraffin-embedded tissues were sectioned (7 pM) in a Leica RM165 
microtome (Germany) and fixed (PFA 4%). Apoptotic nuclei were detected using the 
In Situ cell death detection kit (Roche, Switzerland). Images were acquired in a Zeiss 
Axioimager A .l fluorescence microscope (Carl Zeiss, Germany).
9. Analysis of mitochondrial morphology and dynamics in MEFs
9.1. Plasmids transfection
All plasmids transfections were performed using the Lipofectamine 2000 
reagent (Invitrogen, CA, USA). Four hours after transfection, medium was replaced 
with a growth medium containing antibiotics.
The plasmids used in our experiments were: GFP-LC3 (52), GFP-myc-Parkin 
and DsREDmito, which are a kindly gift of Prof. Wolfdieter Springer (University of 
Tubingen) and Prof. Luca Scorrano (University of Geneva) respectively.
9.2. Analysis of mitochondrial morphology
In vitro morphological analysis of mitochondria was performed by 
transfection of the DsREDmito plasmid into MSD and control iMEFs. Cells from four 
independent experiments were analyzed (~ 185 cells/experiment) and classified 
following a pre-established criteria of mitochondria size/shape.
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9.3. Analysis of mitochondrial dynamics
Plasmids couples GFP-LC3/DsREDmito and GFP-Parkin/DsREDmito were co­
expressed in MEFs. 24 hours after transfection, cells were treated with 20pM CCCP 
(Sigma-Aldrich, MO, USA) for 20 hours. Cells were fixed in PFA 4% and mounted in 
vectashield + DAPI (Vector laboratories, CA, USA).
Images were acquired in a Zeiss LM 710 confocal microscope (Germany) with 
a 63x/1.4 Oil DIC Plan Apo lens. Laser lines at 488 nm (GFP) and 561 nm (DsRED) 
were used.
10. Data Analysis
10.1. Immunoblotting quantification
Quantification of immunoblotting bands was performed using the Image J 
software. For all experiments, data from four control and four MSD mice were 
processed and the average was expressed as the fold-change respect to control.
10.2. Statistics
Data were analyzed by Student's t distribution. A p-value < 0.05 was 
considered statistically significant.
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1. Morphologically- altered mitochondria accumulate in a tissue- 
specific and time-dependent manner in MSD
In order to evaluate the pattern of mitochondrial accumulation, we 
determined the content of mitochondria in two of the most affected tissues of MSD 
mice: brain and liver. For this purpose we used COX IV, a component of the 
mitochondrial electron transport chain, which has been widely used as a marker for 
quantifying the number of mitochondria (56). Levels of COX IV were determined by 
western blot analysis on brain and liver total homogenates obtained from MSD 
(n=4) and control mice (n=4) at four different ages (P15,1-, 2- and 3 months) (figure 
17). In MSD brain, levels of COX IV were comparable to control mice (P15, 0.85 ± 
0.04; 1 month, 0.80 ± 0.07; 2 months, 1.02 ± 0.02; 3 months, 1.01 ± 0.023) thus 
indicating that mitochondrial content remained unaltered over time. The same 
amount of COX IV protein was observed in MSD liver at an early stage compared to 
control (P15, 0.87 ± 0.08; 1 month, 0.97 ± 0.01) whereas increased levels were 
detected at a late stage (2 months, 1.57 ± 0.04; 3 months, 1.32 ± 0.04; p-value< 
0.01). Further analysis of PGCla mRNA levels by qPCR, a master transcriptional co­
activator that controls many genes involved in mitochondrial biogenesis, excluded 
the possibility that the accumulation observed in MSD was due to enhanced 
mitochondrial biogenesis (Brain 3 months, 0.7 ± 0.13; Liver 3 months, 0.91 ± 0.44), 
thus suggesting a defect in mitochondrial removal (figure 18).
Since abnormal accumulation of mitochondria can result in morphological 
changes, we then wondered whether mitochondria from MSD tissues were 
ultrastructurally altered. For this purpose, we measured the size (diameter) of
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mitochondria in both cerebellum and liver ultra-thin sections of control (average 
number of mitochondria measured ~ 53) and MSD mice (av. number of 
mitochondria measured ~ 73) using the Analysis software (figure 19).
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Figure 17. Accumulation of mitochondria in MSD tissues. . Levels of COX IV in brain and 
liver total lysates obtained from MSD (n=4) and control mice (n=4) at P15, 1-, 2- and 3 
months. Here we show the most representative blot as obtained after quantification with 
Image J software. The COX IV/Actin ratio is expressed in terms of fold-change compared to 
control. * *  p-value< 0.01
1.5 i
S 2  0.5 "
□  control 
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Brain Liver
Figure 18. PGCla mRNA levels in MSD tissues. Relative expression of PGCla measured by 
quantitative PCR in both brain and liver extracts of MSD mice (n=3) at 3 months. . Results 
are represented in terms of fold-change compared to control.
Mitochondria of MSD cerebellum exhibited a similar morphology as their 
control littermates at an early stage (control, 498 ± 38; MSD, 503 ± 36) but 
significantly increased in size at 2 months (control, 625 ± 40; MSD, 929 ± 77). 
Surprinsingly, mitochondria appeared smaller (fragmented) at an advanced stage 
(control, 604 ± 43; MSD, 481 ± 18). Morphological analysis of liver samples showed 
that mitochondria of MSD mice (av. num. mitochondria measured = 75) were larger 
(giant) compared to control mice (av. num. mitochondria measured = 56) as soon as 
15 days after birth (control, 994 ± 35; MSD, 1211 ± 30). Similar results were 
obtained at advanced ages (1 month; control, 840 ± 39; MSD, 1760 ± 131; 2 months; 
control, 712 ± 37; MSD, 1112 ± 84; 3 months; control 820 ± 34; MSD, 1277 ± 62).
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Figure 19. Analysis of mitochondrial morphology in MSD tissues. Electron microscopy 
images from cerebellum and liver ultra-thin sections of MSD and control mice (*, 
mitochondria). Mitochondrial size (diameter) was measured using the AnalySIS software on 
EM images obtained from cerebellum and liver ultra-thin sections of MSD and control mice 
at different time points (P15,1-, 2-, and 3 months). Measurements have been expressed in 
arbitrary units (a.u.). * *  p-value< 0.01
The presence of giant mitochondria may be explained by: 1) Enhanced fusion,
2) defective fission and/or 3) impaired mitophagy. We therefore checked for the 
levels of both the fusion protein OPA-1 and the fission protein DLP1 in total brain 
and liver homogenates at 3 months.
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Figure 20. Fusion and fission protein levels in MSD tissues. OPA-1 (left) and DLP-1 (right) 
protein levels in total brain and liver homogenates obtained from MSD (n=3) and control 
mice (n=3) at 3 months. Here we show the most representative blot as obtained after 
quantification with Image J software. Both OPA-l/Actin and DLP-l/Actin ratio are 
expressed in terms of fold-change compared to control. * *  p-value< 0.01
As shown in figure 20 (left), OPA-1 levels were similar to control in both 
brain (1 ± 0.05) and liver (0.99 ± 0.21) of MSD mice thus indicating no changes in
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fusion rates. Similar results were obtained for the fission protein DLP-1 in MSD 
brain (right) (0.90 ± 0.24). On the contrary, DLP-1 levels were dramatically reduced 
in liver (0.05 ± 0.004, p-value< 0.01) when compared to control.
These data suggest that the morphology observed in liver mitochondria of 
MSD may be a consequence of impaired fission. Moreover, these mitochondrial 
alterations are tissue-specific and time-related features of MSD pathology since 
they are mostly observed in liver rather than brain.
2. Mitochondria accumulate outside autophagosome membranes
As previously described in Chapter 4, abnormal mitochondria are recycled by 
mitophagy through their targeting to autophagosomes. However, mitochondrial 
fission is an essential event for proper mitochondrial segregation (42). Defects in 
fission proteins, as observed in MSD liver, might result in impaired mitochondrial 
degradation. Therefore, we investigated whether mitochondria were properly 
sequestered inside autophagic vesicles. To this end, we analyzed the content of 
autophagosomes by electron microscopy (figure 21). Qualitative analysis of ultra- 
thin sections revealed the presence of autophagosomes with fuzzy content in both 
brain and liver of MSD mice. After a detailed analysis of AVs, the number of vesicles 
with no-recognizable structures, called "empty" autophagosomes (eAVs), 
represented out of 35% of the total number of vesicles screened in brain. 
Interestingly, this percentage remained constant over time: P15, 35.7%; 1 month, 
34.9%; 2 months, 33.3%; 3 months, 35.3%. Otherwise, in MSD liver, the percentage
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of eAVs increased over time (P 15, 17.7%; 1 month, 54.3%; 2 months, 47%; 3 
months, 80%) thus suggesting a progressive impairment of autophagic cargo 
sequestration.
To confirm these observations, we transiently co-expressed GFP-LC3 and 
DsREDmito plasmids in MSD and control mouse embryonic fibroblasts (MEFs). As 
previously demonstrated by our group (56), MSD MEFs present a higher percentage 
of depolarized mitochondria in steady-state conditions. Flowever, it is hardly 
difficult to detect a mitophagic event unless depolarization is not exacerbated by 
drug treatments. We then treated cells with CCCP (20pM, 20h), a mitochondrial- 
uncoupling agent that induces mitochondria depolarization and promotes their 
elimination by autophagy (figure 22). Upon CCCP treatment, mitochondria from 
both MSD and control cells appeared fragmented (round-shaped), indicating the 
loss of membrane potential. Under this condition, depolarized mitochondria were 
surrounded by autophagic membranes in control MEFs, as shown by co-localization 
of autophagy-mitochondria markers. On the contrary, only few mitochondria were 
engulfed by autophagosomes in MSD cells even if CCCP treatment was as efficient 
as in control cells. Moreover, as shown in figure 23, a detailed analysis of 
mitochondrial morphology indicated that MSD MEFs presented a higher population 
of intermediate-fragmented mitochondria in both untreated and CCCP- treated 
conditions compared to control.
Together these data indicate that mitochondria accumulate outside 
autophagosomes thus suggesting a defect in the mechanism responsible for 
mitochondrial targeting.
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Figure 21. Analysis of autophagosomes content in MSD tissues. Electron microscopy 
analysis of autophagosomes of cerebellum and liver ultra-thin sections from MSD and 
control mice at 4 different time points (P15, 1-, 2-, and 3 months). Qualitatively, 
autophagosomes of MSD tissues have been classified into two categories: empty AVs 
(white arrows) and filled Avs (black arrows), based on the presence of clearly recognizable 
structures.
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Figure 22. Depolarized mitochondria do not completely co-localize with the autophagic 
marker LC3 in MSD MEFs. Transient co-expression of GFP-LC3 (green) and DsREDmt (red) 
plasmids in MSD and control MEFs. 24-hours after transfection, cells were cultured in 
presence/absence of CCCP (20pM, 20h). Images were taken using a 63x/1.4 Oil DIC Plan 
Apo objective in a Zeiss LSM710 confocal microscope. Merge zoomed area is indicated with 
a white square.
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Figure 23. Mitochondrial morphology in MSD MEFs. Mitochondrial morphology has been 
classified following a pre-established criteria: "Network" for long interconnected 
mitochondria; "Fragmented" as for round-shaped mitochondria; and "Interm ediate" for 
those cells w ith a half-and-a-half pattern. The graph represents the percentage o f cells w ith 
a certain mitochondrial morphology in absence/presence of CCCP (20pM 6h). This value is 
an average value obtained from 4 independent experiments.
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3. Impaired mitochondrial targeting is due to insufficient parkin- 
mediated mitochondrial ubiquitination
During mitochondrial priming, PINK1 recognizes depolarized mitochondria 
and recruits parkin to the OM M , where it exerts its E3 ubiquitin ligase activity. This 
step is crucial for proper mitochondrial recognition and degradation by autophagy. 
Therefore, we analyzed the efficiency of parkin-mediated ubiquitination in MSD 
tissues. To this end, we determined the total amount of ubiquitinated proteins in 
mitochondrial extracts obtained from both brain and liver of MSD and control mice 
(figure 24). . Analysis of the blots reveled equal amounts of ubiquitinated proteins 
in MSD brain mitochondrial fractions except for a slight increase at earl stages (1 
month, 1.17 ± 0.015, p-value<0.05; 3 months, 0.97 ± 0.03). On the contrary, we 
observed lower levels of ubiquitinated proteins per mitochondrial number (ATP|3ase 
content) in MSD liver compared to control (1 month, 0.71 ± 0.04; 3 months, 0.70 ± 
0.05, p-value> 0.05) thus suggesting an incomplete/partial ubiquitination of 
mitochondrial proteins that might probably result into inefficient cargo recognition.
Since OM M  ubiquitination is carried out by parkin, we hypothesized that 
incomplete mitochondrial ubiquitination might be due to 1) inefficient translocation 
and/or 2) reduced levels of parkin. To address this issue, we evaluated the presence 
of parkin in tissue subcellular fractions obtained from both brain and liver of MSD 
and control mice.
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Figure 24. Ubiquitination of mitochondrial proteins in MSD tissues. Analysis of 
ubiquitinated proteins in mitochondrial fractions obtained from MSD (n=4) and control 
mice (n=4) at 1- and 3 months of age. Here we show the most representative blot as 
obtained after quantification with Image J software. Results have been expressed as the 
amount of ubiquitin respect to mitochondrial number. * *  p-value< 0.01
As shown in figure 25, in MSD liver, parkin was predominantly localized in 
mitochondrial fractions when compared to control (1 month, cytosol control 42.2% 
MSD 13.99% p-value< 0.05, mitochondria control 57.7% MSD 86.1% p= 0.32; 3 
months, cytosol control 39.1% MSD 17.6% p= 0.09, mitochondria control 60.8% 
MSD 82.4% p-value= 0.35) although total levels of the protein were significantly 
reduced (1 month, 0.48 ± 0.04; 3 months, 0.35 ± 0.03; p-value< 0.01) (figure 26). 
On the contrary, in MSD brain, parkin levels were comparable to those of control 
mice, being mostly localized in the cytosol (cytosol control 54.2% MSD 64.6% p- 
value= 0.14, mitochondria control 45.8% MSD 35.4% p-value= 0.06) (figure 25) and 
this was associated to unaltered amounts of parkin in total tissue homogenates (1 
month, 1.26 ± 0.1; 3 months, 0.8 ± 0.11) (figure 26).
Proper parkin translocation was further confirmed in MSD MEFs. In this 
case, we transiently co-expressed GFP-parkin and DsREDmito plasmids in MSD and 
control cells, which were then incubated in absence/presence of the mitochondrial 
uncoupler CCCP (20pM, 20h). As shown in figure 27, parkin localization was entirely 
cytoplasmic in untreated cells. Upon CCCP treatment, massive depolarization of 
mitochondria induced the translocation of large amounts of parkin in both types of 
cell thus indicating that parkin is properly recruited to depolarized mitochondria in 
MSD cells.
66
Results
control MSD
m m
u
a>>
GO
E
V)
f l
GO
E
CO
Parkin
p-Actin
COXIV
Parkin
p-Actin
COXIV
ca
u
QQ
V)
f i
GO
E
CO
control 
c m
MSD
m
Parkin
P-Actin
COXIV
Figure 25. Parkin translocates to mitochondria in MSD tissues. Levels of parkin in cytosolic 
and mitochondrial fractions obtained from MSD (n=4) and control mice (n=4) at 1- and 3 
months. Here we show the most representative blot as obtained after quantification with 
Image J software. COX IV has been used as loading control for mitochondrial fraction.
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Figure 26. Parkin levels in MSD tissues. Western blot analysis o f parkin in brain and liver 
total homogenates obtained from MSD (n=4) and control mice (n=4) at 1- and 3 months. 
Here we show the most representative blot as obtained after quantification with Image J 
software. The Parkin/Actin ratio has been expresses in terms of fold-change compared to 
control. * *  p-value<0.01
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GFPparkin
Figure 27. Parkin translocates to depolarized mitochondria in MSD MEFs. Transfection of 
GFP-parkin (green) and DsREDmt (red) constructs in MSD and control MEFs. 24-hours after 
transfection, cells were treated with 20pM CCCP for 20 hours. Images were taken with a 
63x/1.4 Oil DIC Apo Plan lens in a Zeiss LSM710 confocal microscope. Merge zoomed area is 
indicated with a white square.
Our results indicate that despite parkin is able to efficiently translocate to 
mitochondria, levels of this protein are strongly reduced in MSD liver thus providing 
a suitable explanation for the incomplete mitochondrial ubiquitination observed in
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this tissue. Moreover, we found that low parkin levels are likely due to enhanced 
posttranslational alterations since no significant differences were observed in 
PARK2 relative expression (MSD brain, 1 month, 1.26 ± 0.08, p-value< 0.05; 3 
months, 1.29 ± 0.18; MSD liver, 1 month, 0.51 ± 0.31; 3 months, 0.6 ± 0.28) (figure 
28).
□ control ■ MSD
1 month 3 months 1 month 3 months
Brain Liver
Figure 28. PARK2 relative expression in MSD tissues. Analysis by qPCR of PARK2 mRNA 
levels in brain and liver of MSD (n=3) and control mice (n=3) at 1- and 3 months. Results are 
represented in terms of fold-change compared to control. * p-value< 0.05
4. Inhibition of macroautophagy may contribute to defective 
mitochondrial removal
In a previous study, we described a defect in autophagosome maturation in 
LSDs (56, 64). We hypothesize that this autophagic distress may also affect the 
recycling of dysfunctional mitochondria thus exacerbating the mitochondrial 
phenotype already observed.
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Figure 29. Autophagosome accumulation in MSD tissues. LC3 immunoblots on brain and 
liver total homogenates from MSD (n=4) and control mice (n=4) at P15,1-, 2- and 3 months. 
Here we show the most representative blot as obtained after quantification with Image J 
software. Autophagosome accumulation has been expressed as the LC3-ll/Actin ratio in 
terms of fold-change respect to control. * p-value< 0.05; **  p-value< 0.01
71
Results
First, we monitored the accumulation of the autophagic marker LC3-II in MSD 
tissues (figure 29). LC3-ll/Actin ratios in brain and liver total homogenates showed a 
significant accumulation of autophagosomes in MSD mice compared to control, 
both in brain (P15, 3 ± 0.625; 1 month, 1.95 ± 0.05; 2 months, 1.26 ± 0.17; 3 
months, 1.58 ± 0.03) and liver (P15, 1.31 ± 0.15; 1 month, 1.6 ± 0.045; 2 months, 
2.57 ± 0.075; 3 months, 3.2 ± 0.11). Nevertheless, the trend of accumulation 
differed between these two tissues. Indeed, whereas in MSD brain the LC3-ll/Actin 
ratio remained constant over time (except for at P15), LC3-II levels gradually 
increased in liver. These results indicate a distinct autophagic dynamics between 
these tissues, which might be related to different metabolic requirements and/or 
stress conditions of each type of cell. This accumulation of LC3-II was in accordance 
with the block of autophagosome-lysosome fusion already reported (55, 63). 
However, we have never investigated whether this impairment in autophagosome 
maturation may somehow affect autophagy induction. The initial step of 
autophagosome formation depends in part on the phosphorylation-inactivation of 
the mTOR complex and/or levels of Beclin-1, which is part of the complex that 
mediates vesicle nucleation.
Therefore, we evaluated both the levels of Beclin-1 mRNA and protein in 
MSD (n=4) and control tissues (n=4) (figure 30). Immunoblots of MSD brain extracts 
showed a slight increase of protein levels only at 3 months (BECNl/Actin ratio at 
P15, 1 ± 0.03; 1 month, 0.98 ± 0.04; 2 months, 0.99 ± 0.01; 3 months, 1.12 ± 0.006), 
which matched with increased RNAm expression at the same time point (1.41 ± 
0.11, p-value< 0.01).
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Figure 30. Autophagy is induced in MSD brain but not in liver, previous page, Beclin-1 
protein levels in total lysates of brain and liver samples obtained from MSD (n=4) and 
control mice (n=4) at 4 different time points (P15,1-, 2-, and 3 months). Here we show the 
most representative blot as obtained after quantification with Image J software. The 
BECNl/Actin is expressed in terms of fold-change compared to control, this page, BECN-1 
mRNA levels in brain and liver samples from MSD (n=4) and control mice (n=4) at 3 months. 
** p-value< 0.01
Strikingly, Beclin-1 levels in liver were notably reduced at 3 months 
(BECNl/Actin ratio at P15, 0.93 ± 0.06; 1 month, 0.75 ± 0.01; 2 months, 0.95 ± 0.04; 
3 months, 0.3 ± 0.05) although its RNAm expression was comparable to control 
(0.97 ± 0.14, p-value = 0.78). These results suggest that autophagy is differentially 
regulated in brain and liver of MSD mice: whereas in brain we observed a slight 
induction of autophagy at a late stage; in liver we detected reduced levels of Beclin- 
1, which may indicate a post-translational cleavage of Beclin-1 since mRNA levels 
appeared unaltered.
This inhibition of autophagy induction could further contribute to the 
impairment of mitochondrial removal observed in MSD liver.
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5. Dysfunctional mitochondria release cytochrome c and trigger cell 
death in a tissue-specific fashion as a consequence of impaired 
mitophagy
Incomplete removal of mitochondria can have serious consequences for cell 
integrity. We have previously described a tissue-specific accumulation of 
morphologically altered mitochondria in our mouse model of lysosomal storage 
disorders.
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Figure 31. Loss of mitochondrial membrane integrity in MSD tissues. Measurement of JC-1 
incorporation (JC-1 FLU/mg protein) in freshly isolated mitochondria obtained from brain 
and liver of MSD (n=3) and control mice (n=3) at three different stages (P15, 1- and 4 
months). Values have been expressed in terms of fold-change respect to control. * p-value< 
0.05; **  p-value< 0.01
In order to evaluate whether these mitochondria were potentially dangerous 
for cells, we performed a detailed analysis of mitochondrial functionality in MSD 
tissues. Initially, we evaluated the integrity of the mitochondrial membrane using 
JC-1, a fluorescent cationic dye that accumulates in mitochondria with intact 
electrochemical gradient. For this purpose we isolated mitochondria from both 
brain and liver of MSD (n=3) and control mice (n=3) and measured the 
incorporation of JC-1 (figure 31). Isolated mitochondria from MSD brain showed less 
retention of JC-1 at both 1 month (0.83 ± 0.03, p-value <0.05) and 4 months (0.83 ± 
0.15) although the later result was not significant (p-value= 0.35). In liver, loss of 
membrane potential was evident at 1 month (0.67 ± 0.24, p-value= 0.27) and 
became significant at 4 months (0.65 ± 0.015, p-value< 0.01).
Since mitochondria are the main source of energy in cells, we used an ATP 
assay to further evaluate mitochondria functionality. For this analysis we used 
freshly isolated mitochondria from both brain and liver (n=3) and measured the 
relative amount of ATP in each mitochondrial fraction (figure 32). Although the 
results obtained in brain mitochondria were not significant (2 months, 0.61 ± 0.07, 4 
months, 0.82 ± 0.06; p-value > 0.05) they showed a slight decrease in ATP content in 
MSD compared to control mice samples. Instead, mitochondrial fractions from MSD
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liver displayed a striking decrease in ATP levels at both time points (2 months, 0.19 
± 0.1; 4 months, 0.19 ± 0.04; p-value < 0.05).
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Figure 32. ATP content in mitochondria from MSD tissues. Measurement of ATP (ATP * pg 
mitochondrial protein'1) in freshly isolated mitochondria from brain and liver of MSD (n=3) 
and control mice (n=3) at 2 different time points (2- and 4 months). Values have been 
expressed in terms of fold-change respect to control. * p-value< 0.01
Decreased ATP levels and increased permeabilization of the mitochondrial 
membrane can determine the fate of a cell. The opening of MPT pores can lead to 
mitochondrial swelling, OMM rupture and release of pro-apoptotic factors such as 
cytochrome c (41). We therefore evaluated whether mitochondria from brain and
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liver of MSD mice were prone to release cytochrome c from the intermembrane 
space (IMS).
Cytochrome c
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Figure 33. Analysis of cytochrome c release in MSD tissues, top, Western blot analysis of 
cytochrome c in subcellular fractions obtained from brain and liver samples of MSD (n=4) 
and control mice (n=4) at 4 different stages (P15, 1-, 2-, and 3 months). Here we show the 
most representative blot as obtained after quantification with Image J software, bottom, 
percentage of cytochrome c in cytosolic fractions from liver of MSD and control mice. **  p- 
value< 0.01
To this end, we isolated brain and liver samples from MSD (n=4) and control 
mice (n=4) at 4 different time points (P15, 1-, 2- and 3 months). Each sample was
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processed separately and subcellular fractions were obtained by differential 
centrifugation. Equal amounts of both cytosolic and mitochondrial fractions were 
loaded into a SDS-PAGE followed by incubation with an antibody against 
cytochrome c. As shown in figure 33, no traces of cytochrome c were observed in 
cytosolic fractions of MSD brains at any of the stages analyzed. Nevertheless, we 
detected high levels of cytochrome c in cytosolic fractions of MSD liver as soon as 1 
month of age (% Cyt c in cytosol at 1 month= 52.9 ± 5.6, 2 months= 71.1 ± 22.8 and 
3 months= 51.1 ± 2.2). These data are consistent with the results shown in previous 
figures, that is, changes in mitochondrial morphology and membrane permeability 
precede the release of cytochrome c in liver but not in brain of MSD mice indicating 
that cell death is either mediated by different pathways or effectors in these 
organs.
To test whether the release of cytochrome c lead to cell death we 
performed an in situ apoptosis assay (TUNEL) on fixed- paraffin brain (cerebellum 
and cortex regions) and liver sections of MSD mice at an advanced stage of the 
disease (3 months) (figure 34). As expected, no TUNEL positive cells were detected 
on brain slices of MSD mice. This result correlates with the absence of cytochrome c 
in brain cytosolic fractions as shown by immunoblots. The absence of TUNEL 
positive cells suggests that commitment of cell death is mediated by a cytochrome 
c-independent mechanism in this tissue. Contrarily, MSD liver sections exhibited a 
massive presence of TUNEL positive cells per area analyzed.
Hence, we can conclude that mitochondria are the main effectors of cell 
death in MSD liver by releasing cytochrome c and subsequently activating 
downstream caspases.
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Figure 34. Release of cytochrome c triggers cell death in MSD liver. Detection of apoptotic 
nuclei (green) on brain (cerebellun and cortex regions) and liver paraffin sections (7pM) of 
MSD and control mice at 3 months by TUNEL assay. Images were taken in a Zeiss 
Axioimager A .l fluorescence microscope (20x objective).
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CONCLUSIONS
Mitochondrial aberrations are a hallmark of many neurodegenerative 
disorders. In Alzheimer's disease (AD), beta-amyloid (A(5) fragments have been 
described to directly interact with mitochondria thus resulting in mitochondrial 
dysfunction (66). Over-expression of wild-type APP in both M17 and primary 
hippocampal neurons induced a severe mitochondrial fragmentation concomitantly 
with a reduction in the number of mitochondria (67). However, evidence showing 
mitophagy in AD is scarce and controversial: whilst Moreira and collaborators (68) 
showed increased mitochondrial sequestration in autophagosomes, a previous 
study had demonstrated cytosolic accumulation of mitochondria as a result of 
inefficient autophagic-lysosomal degradation (69). Similar to AD, mutant huntingtin 
(htt) has been described to localize to the mitochondrial outer membrane (OM M ) in 
Huntington disease (HD) (70). The association of mutant htt with mitochondria is 
responsible for structural changes, decreased mitochondrial trafficking and 
impairment of mitochondrial dynamics (71). Recently, a study carried out by 
Martinez-Cuervo and collaborators (53) have revealed the existence of cargo 
recognition defects that result in the accumulation of dysfunctional mitochondria in 
HD cells.
Mitochondrial dysfunction has also been involved in the pathogenesis of 
lysosomal storage disorders. Recently, Sano and collaborators (72) reported that 
the accumulation of GM1 at the mitochondria-associated ER membranes leads to 
calcium-dependent mitochondrial apoptosis. Changes in mitochondrial morphology
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and function have been described in a list of different LSDs (see Chapter 4 - 4.3). 
However, while in AD and HD mutant proteins directly have been shown to interact 
with mitochondria, the origin of organelle dysfunction in LSDs may be associated to 
different mechanisms indirectly correlated with the storage.
As previously demonstrated by our group, the accumulation of effete 
mitochondria was initially related to an impairment of autophagosome maturation 
(56, 64). Nevertheless, the results obtained in the present study demonstrate that 
mitochondria accumulation is not a mere consequence of defective 
autophagosome-lysosome fusion but may involve a more specific mechanism that 
mediates mitochondrial priming and targeting to autophagosomes. Furthermore, 
our findings highlight the tissue-specificity of this phenomenon, which appeared to 
be compromised in liver but not in brain of MSD mice.
In brains of MSD mice, we have reported the up-regulation of PARK2 
expression and the increase in parkin levels. We believe that this higher 
transcriptional activation may more efficiently control the elimination of potentially 
dangerous mitochondria. In fact, as consequence of higher parkin activity indicated 
by the increased levels of ubiquitination of mitochondrial fractions, we do not 
observe any differences in mitochondrial content. Moreover, the characterization 
of isolated mitochondria from MSD brain did not reveal significant changes in either 
mitochondrial integrity (JC-1 assay and cytochrome c release) or functionality (ATP 
production). Only at an advanced stage of the disease, presumably as a 
consequence of accumulated metabolic stress, mitochondria from cortical neurons 
appeared fragmented. Mitochondrial fission has been demonstrated to trigger 
autophagy (73). In fact, simultaneously to morphological changes, we observed an
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increase of beclin-1 levels. The induction of autophagy may reflect the urgent 
necessity to eliminate fragmented mitochondria that might compromise tissue 
homeostasis. In a previous study, loss of Purkinje cells has been described in MSD 
mice as soon as 2 months (28). However, no TUNEL-positive cells have been 
detected at any of the stages analyzed. We therefore speculate that, under the 
third month of age, neurodegeneration may not be directly correlated with 
mitochondria dysfunction but might result as a consequence of both direct 
accumulation of undegraded material inside lysosomes and the formation of toxic 
aggregates due to impaired autophagosome maturation (56).
Contrarily to what observed in brain of MSD mice, the analysis of liver 
samples showed a time-related accumulation of mitochondria as indicated by COX 
IV levels. Morphological analysis revealed an increase in mitochondrial size, a 
characteristic that was detected as soon as 15 days after birth. Mitochondrial 
enlargement can be a consequence of 1) defective fission, 2) a high rate of fusion 
and 3) impaired mitophagy. We have reported a reduction in DLP-1 levels, which 
may in part account for the accumulation of enlarged mitochondria. However, in 
the majority of cases, the presence of giant mitochondria is a result of defective 
mitochondrial turnover (74). Actually, the qualitative analysis of autophagosome 
content revealed the presence of a high percentage of vesicles without any 
recognizable structure inside. Notably, this percentage increased over time 
concomitantly with the accumulation of mitochondria. From a detailed analysis of 
key steps of mitophagy emerged that, despite proper translocation, reduced levels 
of parkin resulted in inefficient ubiquitination of mitochondrial proteins in MSD 
liver. We hypothesize that this incomplete ubiquitination might in turn derive in an
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inadequate cargo recognition by the adaptor protein p62/SQSTMl. However, 
further analysis need to be performed in order to check whether p62/SQSTMl is 
able to recognize ubiquitinated mitochondria in MSD. On the other hand, the non­
induction of autophagy, represented by unaltered levels of beclin-1, together with a 
defect in autophagosome maturation may contribute to the phenotype observed by 
limiting the availability of new autophagic vesicles. Moreover, at an advanced stage 
of the pathology, beclin-1 levels appear surprisingly reduced. It has been reported 
that the mitochondrial proteins Bcl-2 and Bcl-XL negatively regulate autophagy by 
binding beclin-1, which is then cleaved by caspases (75). These data indicate that 
apoptosis and autophagic cell death cannot co-exist in the same cell. In line with 
this, our data demonstrate that the impaired removal and subsequent 
accumulation of mitochondria may trigger apoptosis thus leading to autophagy 
inhibition. In fact, detailed analysis of mitochondrial functionality showed the 
collapse of mitochondrial membrane potential (ipm). Many mitochondrial reactions 
such as ATP generation, ROS production and Ca+2 uptake depend on mitochondrial 
MJm. Therefore, loss of membrane integrity results in a strong decrease in ATP 
content and in the opening of the MTP pore, leading to the release of pro-apoptotic 
proteins. In MSD liver, cytochrome c has been detected in cytosolic fractions as 
soon as 1 month of age. Once released, cytochrome c contributes to the formation 
of the apoptosome, which in turns recruits caspases and triggers a cascade of 
events leading to cell death. Actually, TUNEL analysis on liver sections have 
confirmed the presence of many apoptotic nuclei in MSD sections thus indicating 
that in this tissue, mitochondrial dysfunction is directly linked to cell death by the 
release of pro-apoptotic factors
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We believe that the differences observed in our study might be associated 
to tissue energetic requirements. Mitochondria are the main power- house of cells 
since the major production of energy (ATP) occurs through oxidative 
phosphorilation. The brain contains a mixture of both post-mitotic (neurons) and 
mitotic (astrocytes and microglia) cell types. Neurons contain a high number of 
mitochondria, approximately 10,000 mitochondria per cell, which play an important 
role in synaptic maintenance through their ability to buffer Ca+2. For this reason, 
post-mitotic cells are expected to be particularly vulnerable to changes in 
mitochondrial activity. It is then not surprising that mitochondrial turnover would 
be a very tightly controlled event in neurons since oxidative damage is considered 
one of the principal mediators for the progressive decline in cellular function. 
Actually, it is believed that neuronal populations subjected to higher levels of stress 
have higher levels of autophagy that allows the proper removal of ROS-producing 
mitochondria. In fact, not all neurons show the same level of susceptibility to 
impaired autophagy thus supporting the existence of different compensatory 
mechanisms. In fact, in a recent study, Van Laar and collaborators (76) have 
hypothesized the existence of a parkin-independent mechanism of mitochondrial 
turnover that would depend on cellular ATP levels. However, further analysis must 
be performed to corroborate this theory.
We have proposed a new working model (figure 35): in non-pathological 
conditions, parkin molecules are able to recognize depolarized mitochondria and 
promote their elimination by autophagy. In MSD, reduced levels of parkin impair 
the degradation of mitochondria thus leading to the accumulation of
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morphologically and functional- altered mitochondria. At the same time, the block 
of autophagosome and lysosome fusion may in turn contribute to the phenotype 
observed by inhibiting the formation of new autophagic vesicles.
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Figure 35. Proposed working model.
It is not clear whether the reduced levels of parkin are a consequence of 
impaired autophagy or it is an independent cause non-related to defects in 
autophagy. Parkin degradation is controlled by another E3 ubiquitin ligase called 
Nrdpl. The over-expression of Nrdpl has been described to reduce the half-life of 
parkin from 5 to 2.5 hours (77). However, further studies must be performed in 
order to understand the real causes of parkin reduction and whether it can be 
directly correlated to SUMF1 deficiency.
Conclusions
In addition, it would be interesting to transduce MSD liver with a vector 
expressing PARK2 and analyze whether the introduction of exogenous parkin is able 
to rescue the phenotype observed in this tissue. Actually, the analysis of parkin 
translocation in MEFs (GFP-Parkin/DsREDmito) was performed upon parkin over­
expression conditions. It is possible then that what we observed in cells was a result 
of parkin over-expression, which might in turn mask the real phenotype.
Recent publications have described a parkin-dependent proteasomal 
degradation of OMM proteins, which seems to be a critical step for mitophagy (78- 
80). Moreover, other studies showed that p62/SQSTMl- null cells have no defects 
in parkin-mediated mitophagy thus suggesting that this cargo adaptor merely 
participates in mitochondrial aggregation around the perinuclear region (81,82). 
These new observations rise up the necessity to further analyze this selective 
process to better understand its real function.
Differently to other prototypical neurodegenerative disorders such as AD 
and HD, MSD is characterized not only by progressive neurodegeneration but has a 
prominent involvement of many systemic organs. In fact, from the analysis of 
different tissues at the same age has raise up the existence of different degrees of 
phenotype severity. In this study, many of the markers analyzed have been 
monitored over time thus making possible to correlate some events with the 
progression of the pathology. Establishing the onset of a specific molecular event 
may be of great importance in order to develop new therapeutic strategies. 
Moreover, since neurodegeneration has a slower progression, the generation of a
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_____________________________________________________Conclusions
SUMFl conditional mouse strain in brain would be useful to elucidate the 
contribution of mitochondria to the neurodegenerative process.
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Most lysosomal storage disorders (LSDs) are caused by deficiencies of lysosomal hydrolases. While LSDs 
were among the first inherited diseases for which the underlying biochemical defects were identified, the 
mechanisms from enzyme deficiency to cell death are poorly understood. Here we show that lysosomal sto­
rage impairs autophagic delivery of bulk cytosolic contents to iysosomes. By studying the mouse models of 
two LSDs associated with severe neurodegeneration, multiple sulfatase deficiency (MSD) and mucopolysac­
charidosis type IIIA (MPSIIIA), we observed an accumulation of autophagosomes resulting from defective 
autophagosome-lysosome fusion. An impairment of the autophagic pathway was demonstrated by the ineffi­
cient degradation of exogenous aggregate-prone proteins (i.e. expanded huntingtin and mutated 
alpha-synuciein) in cells from LSD mice. This impairment resulted in massive accumulation of polyubiquiti- 
nated proteins and of dysfunctional mitochondria which are the putative mediators of cell death. These data 
identify LSDs as ‘autophagy disorders’ and suggest the presence of common mechanisms in the patho­
genesis of these and other neurodegenerative diseases.
INTRODUCTION
Deficiencies of specific lysosomal hydrolases in lysosomal 
storage disorders (LSDs) cause accumulation of their unde­
graded target substrates. However, it is not clear if these sub­
strates themselves are the primary mediators of toxicity. 
Indeed, the biological pathways from lysosomal enzyme 
deficiency to cellular dysfunction are still largely unknown 
(1,2). Interestingly, despite the great structural diversity of 
the accumulating substrates in the different LSDs, these dis­
orders share many phenotypic similarities, suggesting the pre­
sence of common pathogenetic mechanisms. Many LSDs are 
associated with progressive and severe neurodegeneration 
which represents the most difficult challenge for their
therapy (2). In previous studies, we detected severe neuro­
degeneration in murine models of mucopolysaccharidoses 
type II and IIIA (MPSII and MPSIIIA, respectively) and of 
multiple sulfatase deficiency (MSD) (3-6).
The degradation of intracellular proteins is performed by 
two major mechanisms: the ubiquitin-proteasome system 
(UPS) and macroautophagy (hereafter referred to as auto­
phagy). The latter is a lysosomal-dependent catabolic pathway 
through which long-lived cytosolic proteins and organelles, 
such as mitochondria, are sequestered by double membrane ves­
icles (autophagosomes) and ultimately degraded after 
autophagosome-lysosome fusion (7). Many of the aggregate- 
prone proteins causing late-onset neurodegenerative conditions, 
such as Huntington’s and familial forms of Parkinson’s
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Figure 1. Accumulation of autophagosomes in MSD brain. (A) Anti-LC3 western blot o f total brain homogenates prepared from 1, 3 and 6-month-old MSD and 
wild-type mice. (B) Immuno-fluorescence staining of LC3 in different brain regions of MSD mice and wild-type littermates. Bar =  15 p.m. (C-F) Electron 
micrographs of both cerebellum (C and D) and cerebral cortex (E and F) from an MSD mouse. A neural process from a Purkinje cell, containing a large auto­
phagosome (black arrowhead) and an enlargement of a portion of a neural process from a Purkinje cell are shown in (C). (D) Three autophagosomes (black 
arrowheads) in Purkinje cells surrounded by a double membrane (arrows) and containing remnants of cellular organelles. Membrane cisterns pile up in 
stacks (white arrowheads) by the autophagosomes. (E and F) Electron micrographs of autophagosomes (black arrowheads) in cerebral cortex. Bar: 
d — 3.0 p.m; e =  1.6 p ,m ;/=  9.3 p.m; g =  5.6 pm.
diseases, are autophagy substrates (8). In addition, knock-out 
of autophagy genes causes abnormal protein accumulation in 
ubiquitinated inclusions and neurodegeneration in mice (9,10).
We hypothesized that LSDs are associated with a lysosomal 
dysfunction that impairs the autophagic pathway ultimately 
leading to cell death. To test this hypothesis, we studied the 
mouse models of two LSDs: MSD, which is caused by the 
deficiency of the sulfatase modifying factor 1 (SUMF1) gene 
involved in the post-translational modification of sulfatases 
(6,11,12), and MPS-IIIA, caused by sulfamidase deficiency 
(13). Our results revealed a block of autophagic pathway 
occurs as a consequence of decreased ability of lysosomes to 
fuse with autophagosomes. This results in the cellular accumu­
lation of toxic substrates which are the putative mediators of 
cell death.
RESULTS
Increased autophagosome number in MSD
We assessed autophagosome number in brain sections from 
MSD mice by using an antibody detecting the autophagosome 
marker LC3 (14). During autophagosome formation, the 
LC3-I isoform is converted into LC3-II, whose amount (com­
pared to actin or tubulin) correlates with the number of autop­
hagosomes (14). LC3-II is the only known protein that 
specifically associates with autophagosomes and not with
other vesicular structures. LC3-II levels were clearly raised 
in whole brain homogenates from MSD mice, compared to 
wild-type littermates at 1, 3 and 6 months of age (Fig. 1A). 
Furthermore, immuno-fluorescence analysis revealed increased 
numbers of LC3-positive vesicles in the cerebral cortex, cer­
ebellum and thalamus of MSD mice, compared to correspond­
ing brain regions of wild-type mice (Fig. IB). Electron 
microscopy evaluation of cerebellum (Fig. 1C and D) and 
cerebral cortex (Fig. IE and F) sections from MSD mice 
showed abnormally abundant autophagosomes. Interestingly, 
the morphology of autophagic vacuoles accumulating in 
MSD mice resembled that of early immature autophagosomes 
(15,16) (Fig. 1C-F), suggesting the presence of a defective 
maturation.
A similar increase in LC3-II levels was observed in mouse 
embryonic fibroblasts (MEFs) and embryonic liver macro­
phages (ELMs) (Fig. 2A)—macrophages were previously 
identified as the primary site of lysosomal storage in MSD 
mice (6). The increase in both number and size of autophago­
somes was confirmed in MEFs by quantitative analysis 
(Fig. 2B and C).
Autophagosome-lysosome fusion is impaired in MSD
Clearance of autophagosomes occurs via fusion with lyso­
somes. We postulated that accumulation of autophagosomes
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Figure 2. Accumulation of autophagosomes in MSD cultured cells. (A) Anti-LC3 western blot o f protein extracts prepared from MEFs and ELMs derived from 
MSD and wild-type mice in both normal and starved conditions. (B) MSD MEFs display several autophagosomes (arrowheads), compared to wild-type. 
Bar =  9.3 p.m. (C) Morphometric evaluation revealed that autophasomes were more numerous and larger in MSD MEFs compared to those observed in wild- 
type MEFs. *P <  0.05.
in MSD is due to defective clearance caused by impaired 
autophagosome-lysosome fusion. To test this hypothesis, we 
analyzed the subcellular localization of the lysosomal 
marker lgpl20 (LAMP1) and the autophagosomal marker 
LC3 by confocal microscopy. These experiments demon­
strated that the extent of lgpl20/LC3 co-localization was sig­
nificantly reduced (ranging from 40 to 50%) in MSD 
compared to wild-type MEFs, thus indicating impaired 
autophagosome-lysosome fusion (Fig. 3A and B). This was 
observed both in normal medium (basal autophagy) 
(Fig. 3A) and in starved cells (induced autophagy) (Fig. 3B).
To characterize this impairment, we used drugs which either 
induce or inhibit autophagy. Autophagy stimulation with rapa- 
mycin increased LC3-II levels in both MSD and wild-type 
MEFs (Fig. 4). Moreover, LC3-II levels in MSD MEFs were 
further increased with bafilomycin A l, an inhibitor 
autophagosome-lysosome fusion (17), alone or in combination
with rapamycin, suggesting that the block of autophagy is not 
complete (Fig. 4).
Decreased ability of MSD cells to degrade exogenous 
aggregate-prone proteins
Defective autophagosome-lysosome fusion may lead to an 
impairment of autophagy. We investigated the ability of 
MSD cells to degrade aggregate-prone proteins which are 
autophagy substrates (18). These include the mutant huntingtin 
and A53T a-synuclein which are involved in Huntington and 
familial Parkinson diseases, respectively. Mutant huntingtin 
exon 1 constructs aggregate readily in tissue culture and 
form inclusions readily visible by light microscopy. The pro­
portion of cells with such inclusion is linearly related to the 
expression levels of the construct (19). The A53T a-synuclein 
construct does not form overt inclusions in the cell lines we
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Figure 3. Defective autophagosome-lysosome fusion in MSD MEFs. (A and B) Co-localization of LAMP1 and LC3 in wild-type and MSD MEFs stained for 
LAMP1 (red) and LC3 (green). Confocal microscopy shows a reduction in the extent of co-localization of LAMP1 and LC3 proteins. The figure was selected to 
illustrate the basis for the assays we have quantified. The number of autophagosome-lysosome fusion events in MSD MEFs was quantified both in normal (A) 
and starved (B) serum conditions, as described in the Methods section.
have studied (20). We expressed these mutant proteins in MSD 
cells to test the functionality of the autophagic pathway. The 
Gln74;Q74 huntingtin, which encodes the first exon of hunting­
tin with 74 glutamine repeats, and the A53T a-synuclein were 
fused to green fluorescent protein (GFP) and transiently 
expressed in both MEFs and ELMs derived from MSD 
mice. Forty-eight hours after transfection, cells were collected 
and GFP-fused proteins were detected by western blot. 
Figure 5A shows an increased accumulation of both types of 
mutant proteins in MSD compared to wild-type cells. In 
addition, immuno-fluorescence analysis revealed that the 
number of GFP-Q74 aggregates was also significantly higher 
in MSD MEFs and ELMs compared to wild-type cells 
(Fig. 5B and C). Notably, when cells were analyzed at 
earlier time points, no significant differences in the accumu­
lation of GFP-Q74 were observed between wild-type and 
MSD cells (Supplementary Material), this indicating that 
only at later time points accumulation of overexpressed pro­
teins occurs. Moreover, GFP alone did not accumulate in 
MSD cells (Supplementary Material) demonstrating that 
increased levels of GFP-Q74 and GFP-A53T are due to
autophagic defective degradation and not to difference in 
transfection efficiency.
Taken together, these data indicate a dysfunction of autop­
hagy with consequent decreased ability of MSD cells to 
degrade aggregate-prone proteins.
Polyubiquitinated proteins progressively accumulate 
in MSD neurons
Autophagy is responsible for constitutive protein turnover (8). 
This function appears to be particularly important in neuronal 
cells and is relevant to neurodegenerative diseases (21,22). 
Knockout of autophagy genes results in suppression of 
autophagy and accumulation of inclusion bodies, which 
contain polyubiquitinated proteins, in neurons (9,10). 
We detected a massive and progressive accumulation of 
ubiquitin-positive inclusions in the cerebral cortex as well 
as in other brain regions of MSD mice by both anti Ub 
immuno-histochemical and immuno-fluorescence analyses 
(Fig. 6A and B and data not shown). Co-localization of 
Ubiquitin with NeuN neuronal marker indicates that
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Figure 4. Evaluation of LC3 levels in MSD and wild-type MEFs after induction and/or inhibition of autophagy. Both wild-type and MSD MEFs were treated 
with indicated drugs. Westem-blot analysis (top) was performed using anti-LC3 antibodies. Quantitation (bottom) was performed by normalizing with actin 
levels. The middle lane in the western blot is a lower exposure of the upper lane.
ubiquitin inclusions are located in neurons (Fig. 6B). Pro­
gressive accumulation of polyubiquitinated proteins was 
also detected by western blotting of brain homogenates 
(Fig. 6C). Importantly, analysis of chymotrypsin-like pro- 
teasome activity in MSD brain at several ages revealed 
that proteasome function is not affected in MSD mice 
(data not shown), indicating that the accumulation of ubi- 
quitinated proteins is due to defective autophagy rather 
than to UPS impairment.
In addition, we found that P62/SQSTM1 significantly 
accumulates (Fig. 6D), and co-localizes with ubiquitin- 
positive inclusions (Fig. 6E) in brain from MSD mice. The 
p62/SQSTMl protein is known to be a common component 
of ubiquitin-positive protein aggregates in neurodegenerative 
diseases (23), being involved in the targeting of polyubiquiti­
nated proteins to the autophagosomes and selectively degraded 
via the autophagic pathway (24).
Accumulation of dysfunctional mitochondria in 
MSD mice
Autophagy also plays a crucial role in the degradation and turn­
over of cellular organelles like mitochondria. Indeed, it has 
been suggested that autophagy selectively degrades dysfunc­
tional mitochondria (25). Fragmented and dysfunctional mito­
chondria have been reported to accumulate in patients with 
mucolipidosis types II, III and IV and in patients with neuronal 
ceroid lipofuscinosis 2 (NCL2), suggesting that lysosomal 
storage in these diseases impairs autophagy-mediated mito­
chondrial turnover (26,27). Electron microscopy analysis 
revealed an increased number of mitochondria in MSD brain 
sections and MEFs (Fig. 7A and B). Consistently, an increase 
of Cox4 (a mitochondrial marker) levels was detected by 
western blotting in MSD brain samples (Fig. 7C). To examine 
the function of accumulating mitochondria, we measured the 
mitochondrial membrane potential (A'Pm) in WT and MSD 
MEFs by using_ a mitochondria-specific voltage dependent 
dye (DiOC6). As shown in Fig. 7D, MSD MEFs show a signifi­
cant reduction in the A'Pm compared to wild-type cells in both 
normal and starved conditions, thus indicating that mitochon­
dria accumulating in MSD are dysfunctional.
Impairment of autophagy in MPSIIIA
Overall, our data identify an impairment of autophagy in 
MSD, leading to the accumulation of polyubiquitinated pro­
teins and of dysfunctional mitochondria. To investigate 
whether this applies to other LSDs caused by defective hydro­
lases, we analyzed the autophagic pathway in the murine 
model of MPSIIIA, which is also associated with severe neu­
rodegeneration (4,5). The results obtained in MPSIIIA mice 
were similar to those of MSD mice. We detected increased 
LC3II levels in MPSIIIA MEFs (Fig. 8A) as well as accumu­
lation of autophagosomes in brain samples (Fig. 8B). Conse­
quently, accumulation of ubiquitin-positive inclusions 
(Fig. 8C) and P62/SQSTM1 (Fig. 8D) were observed in the 
brain of MPSIIIA mice. In addition, electron microscopy 
analysis revealed an increased number of mitochondria in
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Figure 5. Decreased ability of MSD cells to degrade exogenous aggregate-prone proteins. (A) Gln74;Q74 huntingtin (encoding the first exon of expanded hun­
tingtin containing 74 glutamine repeats) or A53T a-synuclein were transiently expressed (48 h) as GFP-tagged proteins along with GFP (GFP proteins:GFP 1,5:1 
ratio) in both MEFs and ELMs derived from MSD and wild-type mice. The amount o f GFP-Q74 and GFP-A53T proteins was then assessed by anti-GFP western 
blot. (B and C) Fluorescence microscopy evaluation of GFP-aggregates in MEFs (B) and ELMs (C) expressing GFP-Q74 huntingtin. Transfected MSD MEFs 
and ELMs displayed a significant increase in percentage of GFP-positive cell containing aggregates compared to transfected wild-type cells. Cell counts were 
performed on three independent experiments and 50 cells were analyzed in each experiment. *P <  0.05.
MPSIIIA brain (data not shown). Similarly to MSD, 
accumulation of toxic substrates was observed in the 
absence of any detectable impairment of proteasome function 
(data not shown).
DISCUSSION
Mucopolysaccharidoses represent a substantial proportion 
(~25%) of all LSDs (28). Our results in MSD and MPSIIIA 
indicate that lysosomal storage in these diseases causes cellu­
lar dysfunction by blocking autophagic protein clearance. We 
provide evidence for this block at both structural (i.e. defective 
autophagosome-lysosome fusion) and functional levels (i.e. 
impaired ability of cells to degrade exogenous aggregate- 
prone proteins, and accumulation of endogenous substrates, 
such as ubiquitinated proteins, P62 and mitochondria).
Accumulation of ubiquitinated proteins was also observed 
in mice with autophagy gene knockouts and likely results 
from increased ubiquitination of substrates by virtue of their 
longer half-lives. These mice show severe neurodegeneration,
suggesting that neurons, compared to other cell types, are 
more susceptible to a block of autophagy. This may be 
because non-mitotic cells cannot dilute accumulating cytosolic 
contents by cell division. This may also explain the prevalence 
of a neurological phenotype in LSDs.
Furthermore, our data provide an explanation for previous 
reports of autophagosome accumulation in other types of 
LSDs, namely Danon disease (15), NCL2 (26,29), Glycogeno­
sis type II (Pompe disease) (30) and Mucolipidosis IV (27). 
Note that these previous studies did not resolve the crucial 
issue if the autophagosome accumulation was due to increased 
formation of autophagosomes (which would lead to incre­
ased degradation of autophagic substrates), or decreased 
autophagosome-lysosome fUsion (which results in decreased 
degradation of such substrates). Clearly, these different scen­
arios result in vastly different pathological consequences. An 
induction, rather than a block, of autophagy was observed in 
NPC types 1 and 2, associated with increased levels of 
beclin-1 expression (31,32). However, NPC represents the 
‘atypical’ type of LSD as it is caused by mutations in 
cholesterol transporters, thus suggesting a direct role of lipid
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Figure 6. Accumulation of ubiquitin-positive inclusions and of P62 in MSD brain. (A) Immuno-histochemical staining of ubiquitinated proteins in the cerebral 
cortex of a 1-month-old wild-type mouse and of 1 and 3 month-old MSD mice. Bar =  30 (xm. (B) Anti-Ub (green) and anti-NeuN (red) immuno-fluorecence of 
cerebral cortex sections derived from MSD and wild-type mice showing the presence of ubiquitin-positive inclusions in MSD neurons. Bar =  20 p,m. 
(C) Anti-Ub western blot from total brain homogenates derived from 1 and 3 month-old MSD mice and wild-type littermates. (D) Western blot analysis of 
total brain homogenates showing progressive accumulation of P62 in MSD. (E) Immuno-fluorescence with anti-P62 (red) and anti-Ub (green) showed significant 
co-localization of P62 with polyubiquitinated proteins in the brain o f MSD mice. Bar =  12 |xm.
trafficking in the regulation of autophagy (32). Accordingly, 
we found no differences in beclin-1 expression between 
tissues from MSD mice and wild-type littermates (data not 
shown).
We propose a model which identifies a block of autophagy 
as a crucial component in the pathogenesis of LSDs (Fig. 9). 
According to this model, lysosomal accumulation of unde­
graded substrates results in defective fusion between auto­
phagosomes and lysosomes and causes a block of the 
autophagic pathway. As a consequence of this block, toxic 
proteins and dysfuctional mitochondria accumulate, ultimately 
leading to apoptosis, either directly or through the induction of 
chronic inflammation and cytokine release (6). Indeed, cells 
with impaired autophagy have an increased susceptibility to 
mitochondria-mediated apoptosis (33,34). It is interesting to 
note that bafilomycin Al, a proton-pump inhibitor which 
attenuates lysosomal acidification, results in similar blocks 
in autophagosome-lysosome fusion as LSDs, suggesting that 
there may be ways that defective lysosomal function feed 
back to inhibit autophagosome-lysosome fusion.
Importantly, we found that the ubiquitin-proteasome degra­
dation is not impaired in our LSD mouse models. Proteasome 
dysfunction may lead to the accumulation of ubiquitinated 
inclusions (35) and has been associated to neurodegenerative 
diseases (36-38). The finding that UPS is functional in our 
LSD models allows us to conclude that the block of autophagy 
pathway is the only mechanism accounting for the accu­
mulation of ubiquitinated proteins which are the putative 
mediators of cell death in LSDs. Interestingly, a recent work 
from Pandey et al. (39) showed that autophagy and protea­
some are compensatory interacting systems, and pointed 
to the role of autophagy in rescuing protein degradation 
deficiency due to the proteasome impairment. This finding 
raises the possibility to exploit new therapeutic approaches 
for LSDs based on pharmacological induction of proteasome 
function in order to compensate for autophagy deficiency.
Our model defines LSDs as ‘autophagy disorders’, resem­
bling more common neurodegenerative diseases such as 
Alzheimer (AD), Parkinson (PD) and Huntington (HD) dis­
eases. While there are major differences in the initial steps 
involved in all these diseases (i.e. impaired degradation of 
polyubiquitinated proteins in LSDs versus expression of 
aggregate-prone proteins in AD, PD and HD), our data 
suggest that they may share common mechanisms suggesting 
the possibility of overlapping therapeutic strategies.
METHODS
Generation of MEFs and ELMs
MEFs were isolated by trypsinization of littermate embryos 
isolated at E14 and grown in DMEM supplemented with 
20% FBS and penicillin/streptomycin. Fetal liver cells were 
isolated from E14.5 embryos by mechanical homogenization 
and filtering through a 40 |xm cell-strained. The cells were 
resuspended in DMEM plus 10% fetal bovine serum and 
allowed to attach to plastic. Adherent macrophages (obtained 
by washing wells in DMEM to remove non-adherent cells) 
were cultured in macrophage medium (PAA) and repurified 
by immune-separation using CD lib-coating magnetic beads
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Figure 7. Accumulation of dysfunctional mitochondria in MEFs and brain of MSD mice. (A and B) Electron microscopy analysis of the brain cortex neurons 
from MSD mice and wild-type littermates (bar: wild-type =  2.1 pm; MSD =  1,8 pm). MSD neurons contain a significantly higher number of mitochondria (m) 
compared to wild type neurons as also evident from quantitative analysis (B) (*P <  0.05). (C) Western blot analysis using antibodies recognizing Cox4, a mito­
chondrial marker, shows increased levels of Cox4 in MSD compared to wild-type MEFs. (D) Wild-type and MSD MEFs were grown in either normal serum or 
starved conditions (4 h). Cells were then stained with 40 nM DiOC6 and 1 pg/ml propidium iodine. AFm was measured by flow cytometry. Propidium iodine was 
used as counterstain. All experiments were performed in triplicate and analyzed using Stat-View software and ANOVA test. Results were considered significant 
i f  P <  0.05.
(MACs technology, Miltenyi Biotec). Macrophages were 
characterized by the expression of MOMA-2, and F4/80 anti­
gens by immuno-fluorescence.
Transfections and drug treatments
Sub-confluent cells (MEFs or ELMs) were transfected using 
lipofectamine™ 2000 (Invitrogen) according manufacturer’s 
protocols. For co-localization experiments in normal serum con­
ditions, sub-confluent MEFs were co-transfected with 0.5 |xg 
Igpl20-GFP and 1 |xg mCherry-LC3mCherry-LC3 and cultured 
in full medium for 24 h. For drug treatments, cells were treated 
for 14 h with 0.2 mg/ml rapamycin (Sigma), 200 nM bafilomycin 
Al (Upstate).
Cloning of mCherry-hLC3B construct
Human LC3B was subcloned from pGEX-6P-l into pcDNA3 
(Invitrogen) using BamHI and EcoRI (both NEB). mCherry 
pRSET-B was amplified by PCR with the following primers: 
5’-TA CCG AGC TCG GTA CCC GCC ACC AT-3’ and
3’-G CTG TAC AAG CAA GGA TCC TGC-5’. The resulting 
fragments were purified, digested with Kpnl and EcoRI (both 
NEB) and sub-cloned in frame into the 5’ end of hLC3B 
pcDNA3.
Antibodies
Primary antibodies were: rabbit polyclonal anti-LC3 (Novus 
Biological), rat monoclonal anti-mouse LAMP1 (Develop­
mental Studies Hybridoma Bank, Iowa), rabbit polyclonal 
anti-ubiquitin (DakoCytomation), mouse monoclonal anti- 
NeuN (Chemicon), mouse monoclonal P62/SQSTM1 (BD), 
rabbit polyclonal anti-tubulin (Cell signaling), rabbit polyclo­
nal anti-actin (Sigma) and mouse monoclonal anti-COX4 
(Clontech). Secondary antibodies were: goat anti-rabbit or 
anti-rat conjugated to Alexa Fluor 488 or 594 (Molecular 
Probes, Eugene, OR, USA). HRP-conjugated anti-mouse or 
anti-rabbit IgG (Amersham); biotinylated donkey anti-rabbit 
(Jackson ImmunoReasearch).
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Figure 8. Autophagy impairment in MPSIIIA mice. (A) Anti-LC3 western blot of MPSIIIA and wild-type MEFs in either normal or starved serum conditions. 
Quantification of LC3 protein levels shows an increase of the LC3-II isoform in MPSIIIA MEFs in either normal or starved serum conditions. (B) Immuno­
fluorescence staining of LC3 in the thalamus and cerebral cortex of MPSIIIA and wild-type mice. Bar =  7 p.m. (C) Anti-Ub immuno-fluorescence analysis 
of MPSIIIA mouse brain showing accumulation of ubiquitinated proteins (green) in neurons (NeuN marker:red). Bar =  20 pm. (D) Anti-P62 western blot of 
total brain homogenates from MPSIIIA and wild-type mice. The levels of P62 protein are significantly higher in MPSIIIA mouse brain.
Western blot
Cells were lysed in cold lysis buffer (20 mM Tris-HCl, pH 
7.4,150 mM NaCl, 1% TritonX-100) in the presence of pro­
tease inhibitors (Roche Diagnostics) for 30 min on ice. Brain 
tissue samples were homogenized in sucrose buffer, centri­
fuged and resulting supernatants lysed in TritonX-100. 
Proteins were transferred onto nitrocellulose membrane 
(Amersham Pharmacia Biotech). Primary and (HRP)-conju- 
gated antibodies were diluted in 5% milk. Bands were visual­
ized using the ECL detection reagent (Pierce). Proteins were 
quantified by the Bradford method.
GFP analysis and immuno-staining
Cells were grown on coverslips and fixed in PBS pH 7.4 4% par­
aformaldehyde (GFP analysis) for 20 min. Tissues were fixed 
overnight in PBS pH 7.4 4% paraformaldehyde and were 
embedded in optimal cutting temperature compound (Tissue 
Tek). Cryostat sections were cut at 10 m M . For immuno­
fluorescence analysis, cells/tissues were permeabilized and 
incubated with appropriate primary and secondary antibodies 
(diluted in PBS+1% FBS). Immuno-histochemistry was 
performed using Vectastain ABC kit (Vector Laboratories, 
Burlingame, CA, USA) according to standard protocols. 
Cells/tissue slides were mounted and cover-slipped in
glycerol/DAPI and viewed on an epi-fluorescent microscope 
or counterstained with hematoxylin and viewed on a light 
microscope (immuno-histochemical analysis).
Confocal microscopy
For co-localization analysis in normal serum conditions, cover 
slips were blinded and 20 cells per cell line per experiment 
were imaged on a Zeiss Axiovert 200 M microscope with a 
LSM 510 confocal attachment using a x63 1.4 NA Plan 
Apochromat oil-immersion lens. Laser lines at 488 nm 
(Igpl20-GFP) and 543 nm (mCherry-LC3) were used. The 
detector pinholes were set to give a 0.9 p.m optical slice. 
Acquisition was performed using Zeiss LSM 510 software. 
These cells were then analysed in Zeiss LSM Image Browser 
3.5 as follows: first, only mCherry-LC3+ vesicles were 
counted and marked, by switching off the GFP-channel. 
Then, the GFP-channel was switched back on and the 
number of co-localized vesicles was counted. From these 
two values, the fraction of co-localized vesicles was then 
determined. The number of autophagosome-lysosome fusion 
events in starved MSD and wild-type MEFs were determined 
by the analysis of confocal images [obtained by a Leica TCS 
SP2 AOBS confocal microscope with a x63 Neofluor 
Pan-Apo 1.3 nm oil objective with laser lines at 488 nm 
(LC3) and 594 nm (LAMP1)] utilizing Volocity 3.7.0 software
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Figure 9. A proposed model for the pathogenesis of LSDs. A defect in lyso­
somal degradation results in the accumulation of substrates in the lysosomes. 
Lysosomal storage leads to a reduced ability o f lysosomes to fuse with auto­
phagosomes with a consequent block of autophagy. Polyubiquitinated protein 
aggregates and dysfunctional mitochondria accumulate and promote 
apoptosis-mediated cell death. The inflammatory response to cell damage 
further contributes to cell death.
(Improvision). Pearson’s correlation was used as a value of 
co-localization between autophagosomes and lysosomes.
Mitochondrial membrane potential measurements
PBS-washed 1 x 106 cells were incubated in 40 nM DiOC6 
(Sigma-Aldrich) and 1 ptg/ml PI (Sigma-Aldrich) for 15 min 
at 37°C. After washing, cells were suspended in 1 ml PBS 
(pH 7.4) and were subsequently analyzed using flow cytome­
try. For the DiOC6-stained samples, Pi-negative cells were 
excluded of the analysis. Normal and starved MSD and wild- 
type MEFs were analyzed at the same passage and treated in 
the same way. At least 10 000 cells were analyzed for each 
sample. The experiments were performed at least in triplicate, 
and all statistical analyses were performed using Stat-View 5.0 
(StatSoft, USA).
wild-type MEFs was performed by the point intersection 
method.
Assay of proteasome activity
Chymotrypsin-like activity of 20S proteasomes was measured 
on brain homogenates using Suc-LLVY-AMC as substrate 
(20S proteasome activity assay kit; Chemicon).
Data analysis
Data were analyzed by one-way ANOVA (analysis of var­
iance). A P-value <0.05 was considered to be statistically sig­
nificant. Odds ratios for co-localization LAMP1-LC3 were 
determined by unconditional logistical regression analysis, 
using the general log-linear analysis option of SPSS 9 software 
(SPSS, Chicago).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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Electron microscopy analysis
MEFs were fixed at room temperature, in 2.5% glutaraldehyde 
(Polysciences, Inc., Warrington, PA, USA), 0.1 M sodium 
cacodylate-HCl buffer, pH 7.3, for 10 min, scraped off 
the dish, pelletted by centrifugation and postfixed in 1% 
Os04 (Polyscience) in the same buffer, for 20 min. After en 
bloc staining with 1% uranyl acetate for 1 h and ethanol 
dehydration, cells were embedded in LX112 (Polyscience). 
Tissue preparations were performed as previously described 
(26). Grey-silver sections were visualized using FEICM10 
and Tecnail2G2 microscopes. Morphometry assessment of 
both number and size of the autophagosomes in MSD and
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Cartilage extracellular matrix (ECM) contains large 
amounts of proteoglycans made of a protein core deco­
rated by highly sulfated sugar chains, the glycosamino- 
glycans (GAGs). GAGs desulfation, a necessary step for 
their degradation, is exerted by sulfatases that are acti­
vated by another enzyme, Sulfatase-Modifying Factor 1 
(SUMF1), whose inactivation in humans leads to severe 
skeletal abnormalities. We show here that despite being 
expressed in both osteoblasts and chondrocytes S vm fl 
does not affect osteoblast differentiation. Conversely, in 
chondrocytes it favors ECM production and autophagy 
and promotes proliferation and differentiation by limit­
ing FGF signaling. Thus, proteoglycan desulfation is a 
critical regulator of chondrogenesis.
Supplemental material is available at http://www.genesdev.org.
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2008.
Endochondral ossification, a multistep process respon­
sible for embryonic bone formation and postnatal longi­
tudinal bone growth (Kronenberg 2003), begins once 
mesenchymal cells condense, forming the blueprint of 
the future skeleton. Then, these mesenchymal cells dif­
ferentiate into resting and proliferating chondrocytes 
j hat express Aggrecan and a (II) Collagen while cells at 
I he periphery express a (I) Collagen and form the peri- 
i :hondrium. Subsequently, chondrocytes in the center of 
his structure further differentiate into hypertrophic
i hondrocytes expressing a (X) Collagen but not Aggre- 
i :an and a (II) Collagen. The extracellular matrix (ECM)
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secreted by hypertrophic chondrocytes allows vascular 
invasion, degradation of the calcified ECM, and initia­
tion of osteogenesis. Thus, the ECM plays important 
functions during skeletal development (Olsen et al. 
2000).
Alongside collagen fibrils the cartilagineous ECM con­
tains large amounts of proteoglycans that protect these 
fibrils and provide resistance against compression. Pro­
teoglycans are composed of a protein core to which one 
or more highly sulfated polysaccharide chains (glycos- 
aminoglycan [GAG]) bind. The GAGs moiety of proteo­
glycans can regulate the distribution and binding ability 
of several signaling molecules, thereby influencing de­
velopmental processes. GAGs fulfill these functions ac­
cording to their degree of sulfation (Esko and Selleck 
2002; Perrimon and Hacker 2004) a process determined 
by two classes of intracellular enzymes: the sulfotrans- 
ferases, that catalyze incorporation of sulfated groups 
into a nascent molecule, and the sulfatases, that remove 
them (Diez-Roux and Ballabio 2005; Bulow and Hobert
2006).
There are at least 17 different sulfatases in vertebrates, 
whose function is determined by their subcellular local­
ization in the lysosomes, cell surface, or ER/Golgi, and 
by substrates specificity (Diez-Roux and Ballabio 2005). 
In addition, sulfatase becomes active following a post- 
translational formylglycination catalyzed by the enzyme 
Sulfatase-Modifying Factor 1 (Sumfl) (Cosma et al. 
2003). To date, no other substrates besides the sulfatases 
have been identified for Sumfl (Diez-Roux and Ballabio 
2005); hence, it can be viewed as the master regulator of 
proteoglycan desulfation. Further underscoring the bio­
logical importance of Sumfl and of proteoglycan desul­
fation a broad spectrum of diseases, most of them includ­
ing skeletal abnormalities, results from loss of function 
mutations in various sulfatases or in Sumfl itself (Diez- 
Roux and Ballabio 2005). In most of these diseases, called 
mucopolysaccharidoses, the lack of lysosomal sulfatases 
causes a block in GAG degradation and an intralyso- 
somal GAG accumulation (Neufeld and Muenzer 2001).
In order to define the importance of proteoglycan des­
ulfation during skeletogenesis we studied mice lacking 
Sum fl (Settembre et al. 2007). We show here that al­
though Sum fl is expressed in osteoblasts during skeleto­
genesis, it has no overt function in osteoblasts. In con­
trast, Sum fl and, as a result, proteoglycan desulfation, 
favors ECM production, chondrocyte autophagy, and 
promotes chondrocyte proliferation and differentiation. 
Genetic and biochemical evidence show that Sum fl 
regulation of chondrocyte proliferation and differentia­
tion occurs by inhibiting FGF signaling.
Results and Discussion
Sum fl expression during skeletogenesis
To determine whether Sum fl is an appropriate tool to 
study the role(s) of proteoglycan desulfation during skel­
etogenesis we examined its pattern of expression using 
a LacZ  gene inserted in the Sum fl locus (Settembre 
et al. 2007). 3-Galactosidase staining of whole embryos 
showed that Sum fl starts to be expressed in skeletal el­
ements as early as embryonic day 14.5 (E14.5) (Fig. 1A- 
C). Histological analysis revealed that this staining was
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H +/+G +/+
Figure 1. Skeletal development in S u m f l embryos and mice. {A- 
C) X-gal-stained S u m f l E12.5, E14.5, and E16.5 embryos. LacZ 
was expressed in all cartilagineous elements starting at E14.5. (D) 
Femoral growth plate section showing LacZ staining in proliferating 
chondrocytes and osteoblasts. (E) In situ hybridization of Sumfl in 
E16.5 growth plate. |F-H) Alcian blue/alizarin red staining of E16.5 
(F), newborn (G), and P4 (H) wild-type and Sumfl~h embryos and 
mice. (G,H) Femur and tibia magnification of newborn and P4 
Sumfl'1'  and wild-type mice.
equally strong in proliferating chondrocytes of the 
growth plate and in osteoblasts of the developing bones, 
while staining in hypertrophic chondrocytes was weak 
(Fig. ID); in situ hybridization analysis of Sum fl expres­
sion while confirming that Sum fl was expressed in pro­
liferating chondrocytes and osteoblasts also revealed a 
strong expression in hypertrophic chondrocytes (Fig. IE). 
Thus, Sum fl is a molecular marker of all cell types in the 
developing skeleton.
Proteoglycan desulfation affects endochondral 
ossification
As a first approach to study the importance of proteogly­
can desulfation during skeletogenesis we analyzed skel­
etal preparations of Sumfl'*~ embryos and mice stained 
with alcian blue for unmineralized cartilagineous ECMs 
and alizarin red for mineralized cartilagineous and bony 
ECMs. E14.5 S um fl' * '  embryos were indistinguishable 
from wild-type littermates (data not shown), an observa­
tion consistent with the fact that Sum fl is not express in 
the developing skeleton before this stage. In contrast, 
examination of El 6.5 embryos revealed that femurs were 
significantly shorter in S um fl' * '  than in wild-type em­
bryos (3.0 mm wild type vs. 2.8 mm S u m fl'* '; n = 3, 
P < 0.051. This dwarfism, that worsened in newborn 
S u m fl'* ' mice (4.2 mm wild type vs. 3.8 mm S um fl'* '; 
n  = 5, P < 0.01) was generalized, as every bone analyzed
(femurs, vertebrae, mandibles, components of the skull) 
were shorter in S u m fl'* ' than in wild-type littermates 
(Fig. 1F,G; data not shown). These morphological abnor­
malities that were not caused by a decrease in insulin 
growth factor 1 production (Supplemental Fig. 1A), illus­
trate that the extent of proteoglycan desulfation is an 
important determinant of the growth of most skeletal 
elements during embryonic development.
Proteoglycan desulfation affects growth plate  
ce llu la rity
Next, we performed histological and gene expression 
analyses. Consistent with the absence of morphological 
defects in E14.5 S u m fl'* ' embryos there was no differ­
ence in the morphology of the various populations of 
chondrocytes between S u m fl'* ' and wild-type embryos 
at that stage and expression of a j( I I)  Collagen, a marker 
of proliferating chondrocytes, and of ctj(X) Collagen, a 
marker of hypertrophic chondrocytes, was similar in 
S u m fl'* ' and wild-type embryos at E14.5 (Fig. 2A). At 
El 6.5 the zone of proliferating chondrocytes, determined 
by cell morphology and the extent of a j( I I)  Collagen ex­
pression, was significantly shorter in S u m fl'* ' than in 
wild-type embryos (Fig. 2B). The intensity of oi t (X) Col­
lagen expression was also weaker in E16.5 S u m fl'* ' than 
in wild-type embryos (Fig. 2B). At birth, the classical 
columnar organization of the proliferating chondrocytes 
was lost in the Sumfl'*~  growth plate and expression of 
a ^11) Collagen and of at (X) Collagen was again notice­
ably weaker in mutant than in wild-type growth plate 
(Fig. 2C). Remarkably, despite the high level of Sum fl 
expression in osteoblasts, bone formation defined by the 
presence of bone trabeculae and expression of a j( I)  Col­
lagen was not affected by Sum fl inactivation (Fig. 
2B,C,D). Taken together, these results suggest that inac­
tivation of S um fl—i.e., inhibition of proteoglycan des­
ulfation—affects more severely chondrogenesis than os­
teogenesis dining development.
We next investigated whether the weaker expression 
of a j f l l )  and a^X ) Collagen in the S u m fl'* ' growth plate 
was reflecting a decrease in chondrocyte number. We 
observed that there was a significant decrease in chon­
drocyte number in S u m fl'* ' growth plates at El 6.5 and 
at postnatal day 0 (P0) (Fig. 3A), indicating that the ex­
tent of proteoglycan desulfation regulates, in ways stud­
ied below, chondrocyte survival and/or proliferation dur­
ing endochondral ossification.
Proteoglycan desulfation influences ECM production 
and turnover
Since abnormalities in proteoglycan desulfation result in 
lysosomal defects in several tissues in vertebrates (Neu- 
feld and Muenzer 2001), we asked if lysosomal function 
was affected in S u m fl'* ' chondrocytes and/or osteo­
blasts.
Electron microscopic (EM) analysis of wild-type and 
mutant growth plates did not reveal any morphological 
difference between S u m fl'* ' and wild-type chondrocytes 
at E14.5 (Fig. 3C), while in E16.5 S u m fl'* ' embryos and 
newborn mice the cytoplasm of chondrocytes was filled 
with vacuolar structures that had characteristic appear- 
‘ ance of lysosomes filled with GAGs as seen in cells from 
patients affected by mucopolysaccharidoses (Neufeld 
and Muenzer 2001) (Fig. 3D,E, inset; Supplemental Fig.
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Chondrocyte autophagy is hampered in  the absence 
o f proteoglycan desulfation
We next asked what were the mechanisms leading the 
decrease in chondrocyte num ber in S um fl" '"  growth 
plate. There was no overt increase in chondrocyte apo­
ptosis in Sumfl~'"  mice before or after birth (data not 
shown). BrdU incorporation did not reveal any signifi­
cant difference in chondrocyte proliferation between 
S um fl" '"  and wild-type embryos at E14.5 and E16.5 ei­
ther, although chondrocyte proliferation was signifi­
cantly decreased after birth in S u m fl" '"  m ice (Fig. 4A). 
Thus, at least two mechanisms explain the paucity of 
chondrocytes in the S um fl" '" growth plate: a decrease in 
chondrocyte proliferation beyond birth, and another one, 
yet to be determined, during embryonic development.
Macroautophagy (hereafter referred as autophagy) is a 
lysosomal process of cellular self-digestion required for 
turnover of cytoplasmic structure and for producing en­
ergy in conditions of cellular starvation (Mizushima 
2007). Since chondrocytes reside in a hypoxic and avas­
cular environment (Schipani et al. 2001) we hypoth­
esized that autophagy may be a physiological means al-
A  El 4.5 El 6.5 newborn P4
N.cells/0.1mm2 N. cells/0.1mm2 N. cells/ 0.1 mrr/ N.cells/ 0.1 mm2 
wt 313.2 +/-13.2 415.4+/-20.2 359.5+/-32.9 3605+/- 35
Sumfl-/- 303.0+/-14.0 381.0+/-20.8* 295.6 +/-25.3* 281.6+/-30*
Figure 2. Sumfl"'" deficiency affects chondrogenesis but not osteo­
genesis. (A) Hematoxylin/eosin (H/E) staining and in situ hybridiza­
tion analysis of femoral sections. No differences between Sumfl"'" 
and wild-type growth plates are observed in El 4.5 embryos, while in 
E16.5 (fi) and newborn (C) there is a progressive shortening of both 
proliferative and hypertrophic area in  mutant mice. Expression of 
a l(ll)  and al(X ) Collagen was decreased in  newborn Sumfl"'" com­
pared w ith  wild-type mice, a 1(1) Collagen expression was sim ilar in 
wild-type and Sumfl"'"  samples at a ll stages analyzed. (D) Von 
Kossa-Van Gieson staining of femoral sections showed normal m in ­
eralization (black staining) in E16.5 and newborn Sumfl"'" mice. 
Magnification: A-C, lOOx, D, 50x.
IB). Lysosomal vacuolization in osteoblasts was not 
nearly as dramatic, further suggesting that proteoglycan 
desulfation is a more im portant process during chondro­
genesis than osteogenesis (Fig. 3F).
This impaired lysosomal degradation of GAGs in 
chondrocytes led us to ask w hether the am ount of GAGs 
present in the ECM was affected by the absence of Sum fl 
in chondrocytes by measuring the am ount of GAGs in 
wild-type and in S um fl" '"  chondrocytes. As hypoth­
esized, m utant chondrocytes produced 30% fewer m em ­
brane-bound GAGs than wild-type chondrocytes,- GAG 
secretion in the medium was also reduced by 50% (Fig. 
3G). This explained why staining w ith alcian blue, a dye 
marking proteoglycans, was significantly weaker in 
S u m fl" '"  than in wild-type growth plates (Fig. 3H). EM 
analysis of ER and Golgi did not shown any morphologi­
cal differences between wild-type and S um fl" '"  chondro­
cytes at E l6.5 or P0, indicating that the reduced amount 
of ECM is not caused by a block in the GAGs biosyn­
thetic pathway (Supplemental Fig. 1C).
Figure 3. Defective ECM in  Sumfl"'" growth plate. [A] Chondro­
cyte number in  the growth plate proliferative zone. Values are the 
mean ± SD. Student's test (*) P < 0.05. (B) To lu id in  blue staining of 
chondrocostal cartilage of newborn Sumfl"'" and wild-type lit te r ­
mates. Note the presence of cytoplasmatic vacuolization in  
Sumfl"'" chondrocytes. (C) EM analysis of E14.5 Sumfl"'" and w ild- 
type chondrocytes showing no evidence of lysosomal vacuolization 
in  Sumfl"'" embryos. (D,£) Cytoplasmatic vacuoles in  E l6.5 (D) and 
newborn (£) Sumfl"'" chondrocytes filled w ith  amorphous material 
(GAGs) and partially degraded collagen fiber (£, inset). (£) Sumfl"'" 
osteoblasts arc less affected than chondrocytes by lysosomal vacu­
olization. (G) ECM proteoglycan produced by Sumfl"'" and w ild- 
type primary chondrocytes labeled w ith  3H-glucosamine and 
Na35S04. ECM amount was estimated by 3H  and 35S incorporation 
and normalized for cells number. (H) Decreased alcian blue staining 
in  P7 Sumfl"'" compared w ith  w ild-type growth plate.
Sum fl -/- S um fl-/-
Sumfl - / -
*fc,6000
CELLS MEDIUM
^  glucosamine
io .1 oLM.
CELL5 MEDIUM
Na3sS04
1 0 9
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El 4.5 El 6.5 newborn P4
N.BrdU/0.1mm2 N.BrdU/0.1mm2 N.BrdU/0.1mm2 N.BrdU/0.1mm2 
Wt 61.6+/- 7.7 69.6+/- 9.3 40.3+/-10.1 56.1+/-11.9
Sumfl-/- 63.3+/-11.9 72.4+/-6.5 31.7+/- 5.3* 42.8+/- 9.5*
chondrocytes osteoblasts
□ wt
MSumfl-/-
□ wt
Bw t+baf 
■  Sumfl-/-
2 ° ^ -o-wt+baif ® 
3. p l ^ - w t +  3N1A,
ATP content Cell viability
Figured Abnormal autophagy in Sumfl 1 chondrocytes. (A) Number of BrdU 
positive cells present in the proliferative zone ofthe growth plate. Values are the 
mean ± SD. Student's test (*) P < 0.05. |B) EM analysis of newborn chondrochos- 
tal cartilage revealed the presence of autophagosomes in wild-type chondro­
cytes. (Boxed inset) Note the double membrane vesicles surrounding a" portion 
of cytoplasm (arrows). (C) Chondrocyte from newborn Sumfl 1 showing more 
autophagosomes (AV) surrounded by enlarged lysosomes (L). (D) Confocal m i­
croscopy analysis of Sumfl / ;GFP-LC3 and wt;GFP-LC3 growth plate. In GFP- 
LC3 chondrocytes [left] the GFP fluorescence was more diffused throughout the 
cytoplasm while in Sumfl / ;GFP-LC3 it  was aggregated in cytoplasmatic dots 
[right). [E] Western blot analysis showing a 2.5-fold increase in LC3II level in 
newborn Sumfl 1 chondrocytes. No difference was observed m osteoblasts. Val­
ues shown are means of triplicate experiments. (F) Abnormal autophagy in 
Sumfl 1 chondrocytes during serum and nutrient starvation. Wild-type and 
Sumfl / chondrocytes were starved for the indicated period of time, harvested, 
and subjected to LC3 immunoblotting. Sumfl 1 chondrocytes and w ild type 
stimulated w ith Baf presented an increased amount of LC3H compared w ith 
wild-type chondrocytes at all time points analyzed. (G) ATP amount is decreased 
in wild-type chondrocytes when autophagy is inhibited w ith Baf. Sumfl 1 chon­
drocytes displayed a lower level of ATP compared w ith wild-type and Baf treat­
ment did not affected significantly ATP concentration. (H) Wild-type and 
Sumfl 1 chondrocytes were cultured in serum and glucose-free medium for 2 d. 
Wild-type chondrocytes were also treated w ith  baf and 3-methyladenine, an­
other inhibitor of autophagy. Cell viability was monitored after 12 h, 24 h, and 
48 h. ErroT bars represent SEM. Student's test (*) P < 0.05; (**)P < 0.01.
lowing them to survive, and that impairment in this 
process could cause chondrocyte death in Sum fl / em­
bryos. Indeed, EM analysis of E16.5 embryos and new­
born wild-type mice identified vacuoles containing a 
portion of cytoplasm and degraded organelles, a feature 
characteristic of autophagy (Mizushima 2007) (Fig. 4B, 
arrows). Remarkably, the number of autophagosome 
vacuoles (autophagosomes) was greatly increased in mu­
tant chondrocytes (Fig. 4C).
To establish rigorously that the number of autophago­
somes was increased in Sum fl 1 chondrocytes we used 
in vivo and biochemical approaches. First, we generated 
Sum fl 1 mice harboring in all cells a transgene express­
ing a GFP-tagged LC3 protein (Mizushima et al. 2004). 
During autophagy the free cytoplasmatic LC3I isoform 
of the LC3 protein is converted into LC3II, a specific 
marker of autophagosomes (Kabeya et al. 2000). Consis­
tent with an increase in the number of autophagosomes
GFP immunoreactivity was noticeably stronger 
in S um fl 1 ;GFP-LC3 than in GFP-LC3 chondro­
cytes (Supplemental Fig. ID). Moreover, while 
tbe GFP fluorescence-was distributed throughout 
the cytoplasm in wild-type chondrocytes, it was 
clustered in autophagosomes in S um fl 1 ;GFP- 
LC3 chondrocytes (Fig. 4D, arrows). Western blot 
quantification of LC3II proteins showed also a 
2.5-fold increase in S um fl 1 compared with 
wild-type growth plates (Fig. 4E). This was not 
observed in S um fl 1 osteoblasts (Fig. 4E), further 
illustrating that these cells are-not overtly influ­
enced by the absence of S um fl.
Since GAGs accumulation can inhibit lyso­
somal function (Li et al. 2004), we tested whether 
this increase in the number of autophagosomes in 
S um fl-*- chondrocytes was reflecting a failure of 
lysosome to digest autophagosomes by treating 
wild-type and S um fl * chondrocytes with bafi- 
lomycin (Baf), an inhibitor of the autophago­
some-lysosome fusion (Yamamoto et al. 1998), a 
necessary step during autophagy (Mizushima
2007). Baf treatment of wild-type chondrocytes 
triggered an increase in autophagosome accumu­
lation as measured by LC3-II level and a signifi­
cant decrease of energy (ATP) production (Fig. 
4F,G). In contrast, in S um fl 1 chondrocyte the 
level of LC3H was higher tban in wild-type chon­
drocytes, and Baf did not decrease energy produc­
tion significantly (Fig. 4F,G). These results sup­
port the notion tbat autophagy is impaired in 
Sum fl 1 chondrocytes. To determine if this im­
pairment of autophagy could lead to chondrocyte 
death, wild-type and mutant chondrocytes were 
cultured in-glucose-free and serum-free medium, 
a condition in which autophagy is required for 
energy production and cell survival (Lum et al. 
2005). LC3-II immunoreactivity decreased rap­
idly upon nutrient starvation, suggesting that au­
tophagosomes were efficiently digested by lyso­
somes in wild-type but not in S um fl 1 chondro­
cytes (Figr 4F). Moreover, when measured with 
colorimetric assay, cell viability was decreased in 
S um fl * chondrocytes compared with wild-type 
cells (Fig. 4H).
In summary, in vivo and cell-based assays es­
tablish that autophagy is used by wild-type chon­
drocytes to produce energy and suggest that dis­
ruption of intralysosomal GAG digestion impairs au­
tophagy in S um fl * chondrocytes. This impairment in 
turn leads to cell death.
Proteoglycan desulfation regulates chondrocyte 
pro lifera tion and d iffe ren tiation
To explain the decrease in chondrocyte proliferation 
noted in S um fl 1 mice we asked whether S um fl expres­
sion modulates growth factor signaling. We first looked 
at Indian Hedgehog (Ihh), since its signaling is influenced 
in vivo by GAGs (Koziel et al. 2004), but failed to detect 
any difference in the level of expression of Ihh  or of its 
receptor Patched (Ptch) between S um fl * and wild-type 
chondrocytes at E16.5, P0, or P4 (Supplemental Fig. 2; 
data not shown). These observations indicate that S um fl 
deletion does not affect overtly Ihh  signaling during en­
dochondral ossification.
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S u m fn /-,limf1,  SumfW-; Sumft+/- ,  , , ,  
F g f m i -  S um fh /'  F g f m / -  F g f m / -  iu m n '
A i p ^ i [ F  —
DSumft-/+;fgfta+/- B Sumfl-/- B Sumfl-/-;fgfl8+/-
Figure 5. Sumfl regulates FGF18 activity during endochondral os­
sification. (A) H/E staining of femurs showing shortening of 
Sumfl 1 bone length (arrowheads) and its rescue in ~Sumfl 1 
; f g f l 8 mice. Brdu staining (B) and in  situ expression of a l(n) 
Collagen (C) and al(X) Collagen (D) in wild-type [left], Sumfl 1 
[middle), and Sumfl 1 ifgflS*1 mice. (E) Quantification of femoral 
length, BrdU index, and cell number in  newborn wild-type, Sumfl 1 
, and Sumfl / ;fgfl8*/  mice. A t least three mice were analyzed per 
each genotype. Error bars represent SEM. Student's test (*) P < 0.05; 
(**) P < 0.01. (F) Primary chondrocytes from wild-type and Sumfl 1 
mice treated w ith Fgfl8 (20 ng/mL) for the indicated period of time. 
Note the more sustained phosophorylation of ERK and 70S6k in 
Sumfl / than in wild-type chondrocytes following Fgfl8 treatment.
The defect in chondrocyte -proliferation and differen­
tiation noticed in Sum fl 1 mice was reminiscent of 
what is observed in mice harboring an increase in FGF 
signaling (Omitz and Marie 2002). To determine-if FGF 
signaling was increased we generated S um fl 1 mice 
lacking one copy of Fgfl8, a known regulator of chon­
drocyte proliferation (Liu et-al. 2002).- Several lines of 
evidence indicate that proteoglycan desulfation indeed 
regulates, directly or indirectly, FGF signaling.
First, skeletal preparation showed that removing one 
allele of Fgfl8  rescued S um fl 1 mice short stature at P0 
as determined by femur length (Fig. 5A [arrowhead], 
quantification in E). Second, chondrocyte proliferation 
measured by BrdU incorporation, which was reduced by 
20% in the P0 Sum fl 1 , was indistinguishable from 
wild-type in S um fl 1 ;Fg fl8*/  P0 mice (Fig. 5B, quanti­
fication in E). As a result, the zone of hypertrophic chon­
drocytes was larger-, and there was a significant increase 
of growth plate cellularity in S um fl 1 :Fg fl8+/ com­
pared with Sum fl 1 mice (Fig. 5E). Third a1(II) Collagen 
and olj(X )  Collagen expression was restored almost to its 
normal intensity in Sum fl / ;F g fl8+/ newborn mice 
(Fig. 5C,D). Together, these data support the notion that 
the absence of Sum fl results in an increase in FGF sig­
naling, explaining the decrease in chondrocyte prolifera­
tion observed in S um fl 1 mice. Of note, removing one 
Fgfl8 allele did not normalize the chondrocyte number 
(Fig. 5E), indicating that the abnormal autophagy seen in 
the Sumfl / embryos is not secondary to the increase in 
FGF signaling.
To identify the cause(s) of this increased FGF signaling 
in S um fl 1 chondrocytes we first compared Fgfl8  ex­
pression in  Sum fl / and wild-type newborn mice but
failed to detect any significant difference (Supplemental 
Fig. 3), thus ruling out that S um fl is not a regulator 
of Fgfl8  expression. It has been proposed that proteo­
glycans, through their degree of sulfation, modulate 
the affinity of FGFs for their cognate receptors (Bishop 
et al. 2007). To determine if this was the-c-ase in Sum fl '  
mice we stimulated wild-type and S um fl 1 pri­
mary chondrocytes with FGF 18 and measured activa­
tion of FGF signaling. Both the ERK kinase and the 
ribosomal protein S6, which are involved in FGF sig­
naling (Murakami et al. 2004), were more phosphory- 
lated in Sum fl 1 than in wild-type chondrocytes (Fig. 
5F). These results support the hypothesis that S um fl, 
and more generally proteoglycan desulfation, influence 
FGF signaling in chondrocytes during skeletal develop­
ment.
Sulfatases catalyze desulfation of the GAGs moiety of 
proteoglycans in the intracellular and extracellular 
space. These enzymes are substrates of S um fl whose 
only known function is to activate sulfatases. By study­
ing endochondral ossification in S um fl 7 mice we show 
that proteoglycan desulfation regulates several aspects of 
chondrocyte biology. Indeed, the block in proteoglycan 
desulfation caused by S um fl 7 deletion severely de­
creases chondrocytes viability by hampering their capac­
ity to generate enough energy through autophagy to sur­
vive in  their avascular environment. Our data suggest 
that this defect in autophagy is caused, in part, by the 
engulfment of lysosomes by undigested GAGs that leads 
to an impairment of the autophagosome-lysosome fu­
sion (Settembre et al. 2008).
Growth plate cartilage is a hypoxic structure in which 
the transcription factor H if la  is required for chondro­
cytes survival. The fact that hypoxia stimulate autoph­
agy (Mizushima 2007) suggests that autophagy could be 
one pathway through which H if la  allows chondrocytes 
to survive. Moreover, chondrocytes starvation does not 
increase the autophagosome number as commonly ob­
served in other cellular lines, suggesting that in this cell 
type autophagy is a constitutive rather than an adaptive 
pathway.
Our study also shows that proteoglycan desulfation is 
a negative regulator of Fgfl8  signaling during endo­
chondral ossification. This may be a direct consequence 
of the level of desulfation of certain proteoglycans such 
as heparan sulphate proteoglycan (HSPG) rather than a 
secondary effect of the engulfment of lysosomes with 
GAGs. Our results are in  agreement with the notion 
that, in cell culture, ECM proteoglycans, and parti­
cularly HSPG bind members of FGF family (Bishop 
et al. 2007). It is likely that the two main sulfatases 
involved in this regulatory pathways are S u lfl and Sulf2, 
which are strongly expressed in chondrocytes and 
whose substrate is HSPG (Lum et al. 2007). Together, 
our data show that proteoglycan desulfation eventually 
affects several aspects of chondrocyte biology during 
skeletal development not only by determining lyso­
somal function but also by modulating growth factor sig­
naling.
Materials and methods
Animals
Sumfl 1, Fgfl8 1, and GFP-LC3 transgenic mice were described previ­
ously (Liu et al. 2002; Mizushima et al. 2004; Settembre et al. 2007). 
Genotyping was performed by genomic PCR.
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Skeletal preparation
Skeletons were fixed in 100% ethanol overnight and stained with alcian 
blue and alizarin red according to standard protocols. At least three mice 
of each genotype were analyzed per stage.
LacZ staining and BrdU labeling
Embryos were fixed in 1% paraformaldehyde, 0.2% glutalaldehyde, and 
stained overnight with X-Gal (Roche). Specimens were embedded in par­
affin, sectioned at 6 pm, and counterstained with eosin (Sigma). Embryos 
were labeled with BrdU by injecting pregnant females with 500 pL of 10 
mM BrdU 1 h before harvest. BrdU incorporation was detected using a 
Zymed BrdU staining k it (Invitrogen). Three to five embryos/mice were 
analyzed for each genotype and age group. Statistical significance was 
assessed by the Student's test. ([*] P < 0.05; [**] P < 0.01).
Light and electron microscopy
Tibia were fixed in a 4% paraformaldehyde/1% glutaraldehyde fixative 
solution (pH 7.4), in 0.1 M sodium cacodylate buffer, dehydrated in etha­
nol, and embedded in plastic resin. Ultrathin sections (80 nm) were ex­
amined with a transmission electron microscope operated at 80 kV.
Cell cultures, Western blot analyses, and in situ hybridization 
See the Supplemental Material.
Isolation of radiolabeled GAGs
Primary chondrocytes were cultured in presence of 10 pCi/mL Na^SO* 
(25-40 Ci/mg) and 20 pCi/mL D-[6-“H]glucosamine (40 Ci/mmol) for 3 d 
in sulfate and glucose-free medium. GAG extraction, purification, and 
analysis were performed as described previously (Bame and Esko 1989).
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